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ABSTRACT 
 
Diabetic nephropathy has a significant impact on vitamin D status partially due to the 
role of kidney in maintaining renal uptake of 25-hydroxycholecalciferol (25D) and its 
subsequent activation to 1,25-dihydroxycholecalciferol (1,25D). We previously reported that 
feeding high-amylose maize (HAM), a rich source of resistant starch (RS), prevented 
excretion of 25D-vitamin D-binding protein (DBP) and albumin in Streptozotocin (STZ)-
induced type 1 diabetic (T1D) rats. The objectives of the studies described in this dissertation 
were to: 1) determine if dietary RS could prevent excessive excretion of vitamin D 
metabolites and maintain serum 25D levels in Zucker diabetic fatty (ZDF) rats, a well 
characterized animal model of type 2 diabetes (T2D); 2) to conduct dose-response studies to 
evaluate the renoprotective effect of RS following the induction of T1D; and 3) to determine 
the impact of RS on cytokines and hormones involved in the inflammatory process and 
whether the renoprotective actions of RS can be achieved at a lower dose in ZDF rats.    
In the first study described in this dissertation, Lean Zucker (n = 8) rats were fed a 
control diet (LC; AIN-93G diet with 550 g/kg of corn starch) and ZDF rats (n = 8/group) 
were fed either the control diet (DC) or RS diet (DRS; AIN-93G diet with 550 g/kg of HAM) 
for 6 weeks. RS attenuated hyperglycemia by 41% and prevented albuminuria. Additionally, 
urinary 25D and 1,25D in DRS were 90% and 97% lower, respectively, resulting in 41% 
greater serum 25D concentrations (P < 0.001) compared to DC rats. Along with the 
improved renal histopathologic scoring, our data suggest that dietary RS maintained vitamin 
D balance through its protection against diabetes-induced kidney damage. 
In the second study described in this dissertation, we explored the possibility that RS 
would have a nephroprotective effect following T1D onset. Sprague Dawley (SD) rats (n = 8/ 
group), after induction of T1D with STZ, were fed with AIN-93G diet containing 550g/kg of 
corn starch (CS), 550 g/kg of high-amylose maize (HRS), 275 g/kg of high-amylose maize + 
275 g/kg of corn starch (MRS), or 138 g/kg of high-amylose maize + 412 g/kg of corn starch 
(LRS) for 4 weeks. Vehicle-treated SD rats (n = 5) fed AIN-93G diet containing 550 g/kg of 
corn starch were served as non-diabetic control (NDC). Our results showed that RS, 
regardless of dose, did not improve fasting blood glucose levels in T1D rats compared to 
NDC rats. The overall growth rate in NDC rats was 1.7- to 3.3-fold greater than in T1D rats. 
ix 
 
 
 
In comparison with CS rats, MRS- and HRS-rats gained 52% and 72%, respectively, but 
body weight did not differ between LRS and CS rats. Though RS normalized growth pattern 
in T1D rats, no differences were observed in urinary albumin or 25D concentrations in these 
rats regardless of treatments. Despite the improvement of vitamin D status (~15 – 20% 
greater compared to NDC rats) in T1D rats, interleukin-6 (IL-6) was 9 – 31% greater 
compared to CS rats which was strongly correlated to hyperglycemia (r = 0.472, P = 0.02). 
Hence, the potential mechanism by which RS promotes kidney health and reduces 
inflammation could be contingent on glycemic status and thus future work should focus on a 
preventative approach with RS to maximize its beneficial effects in diabetes.  
The objective of the third study included in this dissertation was to examine the 
mechanism underlying the RS-mediated effects on vitamin D balance of and whether lower 
intake of dietary RS would promote kidney health and vitamin D balance in ZDF rats. Here, 
lean Zucker rats (n=5) were used as our control group (LC) and fed a control diet (AIN-93G). 
For comparison to LC rats, ZDF rats (n = 5/group) were fed the control diet (DC), RS diet 
(HRS), or a diet containing 275 g/kg of high-amylose maize and 275 g/kg of corn starch 
(MRS) for 6 weeks. Fasting blood glucose concentrations and hemoglobin A1c% were not 
affected by HRS or MRS diet. Yet, insulin concentrations were 1.5-fold greater and HOMA-
β% was 2-fold greater in HRS rats compared to DC rats, whereas these improvements were 
not observed in MRS-fed ZDF rats. Additionally, HRS rats, when compared to DC rats, 
exhibited a 20% increase in serum 25D concentrations and excretion of vitamin D 
metabolites was blunted. No differences were detected between MRS and DC rats with 
respect to vitamin D balance. Serum triglycerides were 50% lower and liver triglycerides 
were 2-fold greater in HRS rats when compared to DC rats. Circulating adiponectin 
concentrations were 77% greater and serum angiotensin II concentrations were 44% lower in 
HRS rats than in DC rats. No differences in circulating adiponectin and angiotensin II 
concentrations were observed in MRS compared to DC rats. Moreover, adiponectin 
concentrations were highly correlated with vitamin D status (r = 0.815, P < 0.001) and 
urinary creatinine output (r = 0.818, P < 0.001) and inversely correlated with urinary protein 
(r = -0.583, P = 0.02).  
Collectively, though we showed that the effect of 20% RS on promoting kidney 
function and vitamin D homeostasis in ZDF rats may be influenced by circulating 
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adiponectin concentrations, our studies indicate that a 50% reduction in dietary RS does not 
produce the same results. Nevertheless, the studies described in this dissertation indicate that 
HAM could be a part of dietary intervention strategies aiming to prevent or attenuate 
symptoms of diabetic nephropathy that are independent of blood glucose management. 
Because the level of dietary RS used in these studies would be difficult to translate to human 
feeding studies, future work should consider combination strategies with RS and other 
dietary compounds or medications for the prevention and/or management of diabetic 
nephropathy and its associated complications.  
 
1 
 
 
 
CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
The worldwide prevalence of diabetes is expected to reach 439 million by 2030 [1]. 
The increasing burden of diabetes highlights the need for the prevention and management of 
the disease, especially the secondary complications that dictate the morbidity and mortality 
of diabetic patients. Unfortunately, diabetes is a major risk factor for cardiovascular and 
kidney diseases. It is also noteworthy that in the United States, approximately 44% of the 
reported renal failure cases are due to diabetes [2]. Because the kidney plays an essential role 
in nutrient reabsorption, impaired kidney function could lead to severe nutrient deficiencies, 
such as vitamin D deficiency [3], which may further accelerate the progression of diabetic 
complications. In addition to vitamin D reabsorption, the kidney is critical for vitamin D 
metabolism because it activates 25-hydroxycholecalciferol (25D) to 1,25-
dihydroxycholecalciferol (1,25D) for release into circulation [4, 5]. This could partially 
explain the underlying causes of low vitamin D status observed in diabetic individuals [6, 7]. 
Indeed, mounting evidence indicates that the beneficial effects of vitamin D extend beyond 
bone health, and may have a beneficial impact in chronic disease such as cancer, autoimmune 
diseases, and diabetes [8-12]. Hence, optimizing vitamin D status could be a feasible 
approach to delay the secondary complications resulting from diabetes.   
Previous work in our laboratory demonstrated that dietary resistant starch (RS) 
attenuated the symptoms of diabetic nephropathy in streptozotocin (STZ)-induced diabetic 
rats, a widely accepted model of type 1 diabetes (T1D), through the up-regulation of vitamin 
D endocytic proteins, megalin and disabled-2 (Dab2) [13]. RS used for these studies is a 
form of fermentable fiber that is partially resistant to digestion in the small intestine. Not 
only does RS have low glycemic properties, it has been reported that various forms of RS are 
potential substrates for microbial production of short chain fatty acids (SCFA) in the gut. 
Studies have also shown that SCFA was able to reduce abdominal fat and improve insulin 
sensitivity in obese animals [14-16] and that fermentation of RS could lead to improved gut 
health [14, 17]. However, no prior studies reported a benefit of RS with respect to kidney 
health and vitamin D metabolism during the progression of diabetes. Our laboratory 
previously discovered that the loss of vitamin D in the urine is a result of compromised 
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kidney function in Zucker diabetic fatty (ZDF) rats, a well-characterized type 2 diabetes 
(T2D) model [3] and that RS was protective against T1D-induced diabetic nephropathy [13]. 
Hence, the development of my dissertation aimed to investigate the effect of RS on vitamin 
D homeostasis as well as the underlying mechanism in diabetic animal models. The 
objectives of the present research were to: 1) determine if high-amylose maize (HAM), a 
source of RS, could maintain vitamin D balance in ZDF rats (T2D model); 2) determine 
minimal effective dose of RS that could prevent the perturbation of vitamin D metabolism 
and compromised kidney function in STZ-induced diabetic rats (T1D model); 3) investigate 
the mechanism by which RS plays a role in the maintenance of kidney health and vitamin D 
balance in ZDF rats and 4) whether the nephroprotection provided by RS feeding can be 
achieved at lower dose that we have previously utilized.  
 
Dissertation Organization  
 This dissertation consists of six chapters with a general introduction, literature 
review, three manuscripts, and an overall conclusion. The first manuscript entitled “Dietary 
resistant starch prevents urinary excretion of vitamin D metabolites and maintains circulating 
25-hydroxycholecalciferol concentrations in Zucker diabetic fatty rats” has been published in 
the Journal of Nutrition. This manuscript reported the maintenance of vitamin D homeostasis 
and kidney health by RS in T2D animal model. The work presented in the second manuscript 
evaluated the renoprotective effect of RS at a dose-dependent manner utilizing STZ-induced 
diabetic rats and has been prepared for submission to the Journal of Nutrition. The work 
presented in the third manuscript further investigated the mechanisms underlying the 
nephroprotection of RS in ZDF rats, which will be submitted to the Journal of Nutrition. All 
literature cited is based on the format of Journal of Nutrition and listed at the end of each 
chapter. This dissertation will end with a general conclusion that includes a discussion of 
overall results and future directions for my research theme.             
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CHAPTER 2: LITERATURE REVIEW 
 
Diabetes Mellitus 
Diabetes mellitus currently affects ~300 million people in the world [1]. In the United 
States, the prevalence of diabetes in children and adults has reached ~29 million or 9.3% of 
the total population [2]. The diagnostic criteria for diabetes includes: fasting blood glucose 
concentration >126 mg/dL, hemoglobin A1c (HbA1c) > 6.5%, 2-hour plasma glucose > 200 
mg/dL following an oral glucose tolerance test, and random plasma glucose > 200 mg/dL on 
at least two occasions along with classic symptoms of hyperglycemia [3]. Satisfaction of any 
of the above criteria classifies an individual as a diabetic.  
 
Type 1 diabetes (T1D) 
T1D is an autoimmune disorder that is associated with pancreatic beta cell 
destruction, where the most common age at diagnosis falls between 10 – 14 years old [4]. 
Some of the common symptoms observed in T1D are hyperglycemia, polydipsia, polyuria, 
weight loss, and ketonemia [4]. The etiology of T1D is still largely unknown; however, the 
initiation of immune response against beta cells likely begins with the production of 
interferons [5]. The up-regulation of interferons and recruitment of other pro-inflammatory 
cytokines stimulate autoreactive CD8 T-cells to attack beta cells in the pancreas, which will 
eventually lead to beta cell apoptosis. As the autoreactive CD8 T-cells continue to proliferate 
and migrate into the pancreas along with CD4 T-cells and B-cells, the progression of beta 
cell destruction is exacerbated and defective insulin secretion (i.e. T1D onset) occurs [5]. 
One of the candidates reported to be most associated with T1D is the human leukocyte 
antigen (HLA) that is known for its role in immune regulation [6, 7]. Compared to general 
population, children with TID susceptible HLA alleles have ~20-fold greater risk for 
developing T1D [8]. The strongest association with T1D has been related to the HLA class II 
genotype, which may be inherited [9]. It is reported that individuals who have an HLA 
genotype identical with their diabetic proband sibling have 55% greater chance for 
developing diabetes by the age of 12 compared to siblings who share one or less HLA 
haplotype [9]. Unlike the class II HLA genes, evidence of T1D and polymorphisms of class I 
HLA genes is less prominent. Some of the class I HLA genotypes, such as HLA-B39 [10] 
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and HLA-A24 [11], were associated with islet destruction and progression of T1D. However, 
the interactions between class I and class II HLA alleles in T1D are still not well defined and 
how environmental risk factors may contribute to the risk of T1D remain to be determined.   
 Immune cell regulation by the gut microbiota has recently raised a significant 
amount of interest regarding the risk of developing T1D. Evidence from T1D animal models, 
mostly with the utilization of BioBreeding diabetes-prone (BB-DP) and non-obese diabetic 
(NOD) animal models, have suggested that even before the onset of diabetes, the 
composition of the gut microflora in rodents that eventually developed diabetes differed from 
those that remained healthy [12, 13]. Compared to BioBreeding diabetes-resistant (BB-DR) 
rats, the BB-DP rats exhibited lower abundance of Bifidobacterium, Lactobacillus, and 
Pseudobutyrivibrio, which are all known to promote gut health [13]. Wen et al [14] has 
reported that systemic immune responses in the NOD mice were mediated by gut microbiota 
through the MyD88-dependent pathway. MyD88 is an adaptor protein that is capable of 
initiating an innate immune response when coupled with multiple toll-like receptors (TLR). 
Compared to wild-type NOD mice, MyD88-knockout (KO) NOD mice housed in a 
conventional specific-pathogen-free environment were protected from T1D and this was 
correlated with decreased T-cell proliferation in pancreatic lymph nodes. Interestingly, Wen 
et al [14] further demonstrated that MyD88-KO mice developed diabetes when housed under 
germ-free conditions; whereas diabetic incidence and pancreatic islet infiltration in these 
animals was markedly reduced when colonized with commensal bacteria [14]. This suggests 
that gut bacteria could have promoted pancreatic health in NOD mice via a mechanism that is 
independent of MyD88. Although further studies are needed to elucidate and identify the 
regulatory role of gut microflora in the innate immune system and T-cell mediated beta cell 
destruction, these new perspectives could provide alternative options for those who are 
genetically susceptible to T1D.   
 
Type 2 diabetes (T2D) 
T2D constitutes 95% of the total documented cases of diabetes worldwide. It is 
estimated that almost 387 million people are at risk for the development of T2D due to adult 
onset weight gain and a sedentary lifestyle [1]. The risk factors for T2D may include physical 
inactivity, family history of T2D, aging, obesity, and ethnicity. For example, African 
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Americans, Hispanics, and Asians, are at higher risk for T2D development [2]. T2D is 
generally characterized by hyperglycemia and hyperinsulinemia due to insulin resistance, in 
contrast to T1D where insulin production is diminished. The common symptoms of T2D are 
mostly attributed to insulin resistance. Under normal circumstances, insulin secretion is 
initiated in the postprandial state when glucose levels are elevated. An increase in blood 
glucose stimulates the entry of glucose into the beta cells of the pancreas via glucose 
transporter-2 (GLUT2) where the glucose is oxidized for ATP production. Intermediates of 
the TCA cycle, such as NADPH, malonyl-CoA, and glutamate can then serve as signaling 
molecules for insulin secretion. The insulin-signaling cascade begins with the binding of 
insulin to the insulin receptor, which activates the tyrosine kinase domain of the insulin 
receptor beta subunit [15]. This action subsequently promotes tyrosine phosphorylation of 
several substrates, including the insulin receptor substrate (IRS) and phosphatidylinositol 3-
kinase (PI3). Upon the stimulation of PI3, glucose transporter-4 (GLUT4) in the peripheral 
tissues translocates from the cytosol to the plasma membrane to facilitate glucose uptake 
[15]. Although the exact mechanism is not well established, studies have suggested that 
serine phosphorylation of IRS-1, and thus disruption of downstream insulin signaling and 
GLUT4 translocation could be a potential cause of insulin resistance [15]. As insulin 
resistance develops, beta cells continue to proliferate in order to compensate for the demand 
of insulin as a result of hyperglycemia. Due to excessive production of insulin, the ability of 
endoplasmic reticulum (ER) to process pro-insulin into insulin is compromised, which leads 
to the generation of excess misfolded or unfolded proteins that cause ER stress in beta cells 
[16]. It is believed that ER stress response due to prolong exposure to glucose is a critical 
factor that leads to beta cell death in T2D and thus insulin-dependent diabetes [16].           
 
Insulin resistance and adipose tissue inflammation  
The underlying mechanism responsible for insulin resistance and T2D remains unclear. It is 
estimated that 36% of the population in the United States is obese, a condition that has been 
postulated to increase the risk of being diagnosed with T2D by seven times [17, 18]. Because 
low grade inflammation is closely associated with the development of insulin resistance in 
obese individuals [19], it is reasonable to suspect that insulin resistance could be a 
consequence of adipose tissue inflammation as the presence of pro-inflammatory cytokines, 
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such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) may 
disrupt insulin receptor signaling in peripheral tissues as described above [17, 18]. In support 
of this concept, it was found that manifestation of hypertrophic adipocytes in obese adults 
elevated the expression of pro-inflammatory factors and enhanced immune cells infiltration 
into the adipocytes [20, 21]. The subsequent recruitment of pro-inflammatory cytokines 
following macrophage infiltration is thought to be a critical action that amplifies the 
inflammatory signal in adipocytes that later contribute to systemic low-grade inflammation 
[17, 18, 20]. It was also reported that expansion of adipocytes was limited by pro-
inflammatory signals via the suppression of peroxisome proliferator-activated receptor-γ 
(PPAR-γ) and CCAAT/enhancer-binding protein-α (C/EBP-α) activity [22, 23], critical 
proteins involved in adipogenesis and body weight homeostasis. As storage of lipid is limited 
in the adipocytes, ectopic lipid storage and hypertriglyceridemia may occur to augment 
systemic inflammation and insulin resistance if calorie intake becomes excessive [22]. 
Adiponectin, a predominant adipokine primarily secreted by white adipocytes, has been 
suggested to serve as a starvation signal that favorably promotes storage of triglycerides in 
the adipose tissue. In fact, it was observed in transgenic ob/ob mice overexpressing 
adiponectin that despite an increase in total fat mass, these mice exhibited lower liver and 
serum triglycerides, as well as enhanced insulin sensitivity compared to the wild-type ob/ob 
mice [22]. Because transgenic ob/ob mice with overexpressed adiponectin also demonstrated 
increased expression of PPAR-γ in adipose tissue, it was suggested that elevated adiponectin 
levels enhanced the local activity of PPAR-γ, which lead to lipid redistribution to 
subcutaneous adipose tissue and not ectopic lipid storage [22]. Thus, as adiponectin levels 
are inversely related to adiposity [24], the associated insulin resistance commonly observed 
in obesity-related diabetes may be related to ectopic lipid-induced local inflammation 
resulting from adiponectin deficiency.  
 
Insulin resistance and metabolic endotoxemia  
Another possible mechanism that leads to insulin resistance could be related to the 
presence of lipopolysaccharide (LPS), an endotoxin found on the outer membrane of Gram-
negative bacteria. This condition is commonly referred to as metabolic endotoxemia, which 
is characterized by increased concentrations of plasma LPS [25, 26]. Metabolic endotoxemia 
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is highly dependent on feeding status, where LPS levels usually spike during the feeding 
period and remain low during the fasting state [25]. However, this cycle was disrupted in 
mice fed a high-fat diet (HFD) as plasma LPS remained elevated throughout the day. 
Moreover, LPS-infused mice established hyperglycemia, insulin resistance, low-grade 
inflammation, and a marked increase in hepatic triglycerides that mimicked the effect of a 
HFD referred to above [25]. The mechanism underlying metabolic endotoxemia is not 
entirely clear. Because LPS concentrations were inversely correlated with Bifidobacterium 
spp., a known gut barrier protection factor, and the presence of Bifidobacterium in the cecal 
content was strongly associated with improved glucose tolerance and insulin secretion in 
HFD-fed mice, it is reasonable to postulate that excessive caloric intake may have disrupted 
the gut barrier integrity by altering gut microbiota composition. This, in turn, could have 
enhanced LPS absorption in the gut and triggered systemic inflammation in these HFD-fed 
mice [26].  
 
Macrovascular and Microvascular Diabetic Complications 
Uncontrolled diabetes can lead to severe chronic microvascular and macrovascular 
complications such as retinopathy, neuropathy, nephropathy, and atherosclerosis [19, 27, 28]. 
It has been shown that increased oxidative stress, due in part to hyperglycemia, can 
contribute to the pathogenesis of diabetic complications, such as those resulting from the 
formation of free radicals, production of advanced glycation end products (AGE), and 
activation of the polyol pathway [29-31]. Mitochondria are one of the primary sources of 
reactive oxygen species (ROS) during an incomplete electron transfer [32, 33]. 
Overproduction or an inability to remove these free radicals produces oxidative stress, a 
physiological state that can lead to cellular dysfunction, cell death, and chronic diseases such 
as diabetes, aging, and cancer [34-36]. Indeed, production of AGEs due to prolonged 
exposure to high glucose has been linked to enhanced inflammation and oxidative stress in 
diabetes [31, 37-39]. It is believed that the vascular damage by AGEs is partially mediated by 
the structure and functional modification of intracellular proteins and extracellular matrix 
molecules [37, 38, 40]. Binding of AGEs to the AGE receptor (RAGE) has also been shown 
to promote an inflammatory response via the activation of nuclear receptor NF-kB [37, 39].  
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Another pathway that could be centrally involved in the development of diabetic 
complications is the polyol pathway. The polyol pathway can be activated in response to 
hyperglycemia, which in turn can induce local osmotic stress in locations including the 
kidney and retina, as glucose can freely enter insulin-independent organs [41-44]. Under a 
normal glycemic state, glucose has low affinity for aldose reductase, an enzyme responsible 
for catalyzing glucose to sorbitol. In contrast, glucose’s affinity for aldose reductase 
increased during hyperglycemia and glucose was further catalyzed into sorbitol, a reaction 
that oxidizes NADPH to NADP+ [41-43]. Because NADPH is a precursor for glutathione 
production, the formation of sorbitol by aldose reductase could thus reduce the availability of 
glutathione for antioxidant activity indirectly. Simultaneously, sorbitol is able to bind to other 
functional proteins for the production of AGEs, which exacerbates the progression of 
oxidative stress in local tissues such as the kidney and retina.   
 
Atherosclerosis  
Cardiovascular disease is the leading cause of death in diabetic patients [1]. The 
underlying mechanism in atherosclerosis caused by a diabetic condition may be partially 
attributed by the accumulation of AGEs [45, 46]. It has been reported that glycated low-
density lipoprotein (LDL) may accelerate atherogenesis in diabetes through the promotion of 
a chemotactic response in macrophages [45, 47], possibly via the TLR4 signaling pathway 
[45]. Monocytes that migrate into the artery wall can be activated by glycated LDL and 
differentiate into macrophages [45-49].  This is a critical aspect of atherogenesis because 
internalization of modified LDL by macrophages catalyzes the formation of foam cells and 
“fatty streaks” within the artery wall. This process is followed by collagen synthesis, 
attraction and accumulation of platelets, and the eventual formation of fibrous plaques, which 
impede blood flow due to narrowing of the arterial lumen. Fibrous plaques can then become 
complicated, a condition generally characterized by plaque calcification, hemorrhaging into 
the plaque, and thrombosis. Due to these factors, fibrous plaques often rupture to cause acute 
coronary events such as myocardial infarction and ischemia [50].    
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Diabetic retinopathy 
The polyol pathway is one of the major contributors to diabetic retinopathy because 
aldose reductase, the rate-limiting enzyme for the polyol pathway, is abundant in retinal 
ganglion cells, Muller glia, pericytes, and the retina pigment epithelial cells. Hence, these 
cells are more susceptible to damage during the progression of diabetes, when the polyol 
pathway tends to be highly active [44]. This is further supported by the use of aldose 
reductase inhibitors to prevent accumulation of sorbitol and fructose in the retina of diabetic 
rats [51-53], suggesting that the polyol pathway is central to the development of diabetic 
retinopathy. Other key factors involved in the progression of retinopathy are vascular 
endothelial growth factors (VEGF), which have been linked to activation of the hypoxia-
inducible factor, [54, 55], the key regulator of angiogenesis. Studies have reported that 
increased VEGF expression was present during hyperglycemia and enhanced 
neovascularization, vascular permeability, and activation of pro-inflammatory proteins in 
retinal vessels [55-57].  In fact, VEGF production was markedly higher in patients with 
diabetic retinopathy [58, 59], while attenuation of VEGF delayed the progression of 
retinopathy in diabetes [60-62], which indicated that VEGF is highly involved in the 
formation of retinopathy during chronic hyperglycemia.  
 
Diabetic neuropathy 
It is estimated that 60-70% of diabetic patients are affected by neuropathy [63]. 
Peripheral neuropathy is the most common form of neuropathy in diabetic patients. 
Symptoms of peripheral neuropathy include pain and tingling in the arms, hands, feet, or toes 
[63]. Autonomic neuropathy, another form of neuropathy found in many diabetics, manifests 
in various organ systems and can lead to constipation, diarrhea, and cardiovascular 
dysfunction [63-65]. While the etiology underlying diabetic neuropathy is not well-known, it 
is believed that the cause of neural damage is related to polyol pathway activation and 
production of AGEs [66-68]. Juranek et al. [69] demonstrated that RAGE was expressed in 
30% of healthy peripheral nerves, whereas it was observed in more than 40% of diabetic 
peripheral nerves. Furthermore, RAGE deletion in T1D mice improved axon regeneration 
and endoneural vessels after a sciatic nerve crush, a common procedure to induce peripheral 
nerve injury via mechanical compression of the nerve [70]. Notably, it appeared that the 
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repair of nerve fiber regeneration was highly dependent on glycemic stage as no difference 
was detected in non-diabetic RAGE-null mice compared to diabetic RAGE-null mice [70]. 
Though detailed mechanisms by which AGEs and RAGE signaling may contribute to 
diabetic neuropathy requires further investigation, evidence suggests that RAGE plays a 
critical role in the process of neurodegeneration. Thus, strategies that target RAGEs are 
promising in the prevention of diabetic neuropathy.    
 
Diabetic nephropathy  
T2D is the most common cause of kidney disease, constituting 44% of the 
documented renal failure cases in the U.S. [71]. In diabetic kidney disease, the process of 
kidney damage is believed to begin in the glomerulus, where the integrity of the basement 
membrane is compromised, which leads to glomerular leakage of albumin [72-74]. In 
cultured human proximal tubular cells, glucose has been shown to increase the synthesis of 
collagen and fibronectin. Furthermore, thickening of the tubular basement membrane was 
closely correlated with HbA1c levels and AGEs [37, 75]. Accumulation of such extracellular 
matrices in the kidney has been associated with increased fibroblast proliferation and renal 
inflammation [76-78], which may partly explain the common symptoms of diabetic 
nephropathy, such as elevated glomerular filtration rate, proteinuria, and glomerulosclerosis. 
Zucker diabetic fatty rat (ZDF), a well-established T2D animal model, exhibits glomerular 
hypertrophy and hyperfiltration as early as 5 months of age due to the damage of podocytes, 
which has been linked to the formation of an abnormal glomerular basement membrane 
structure [74]. In in vitro studies, glucose-treated kidney cells were shown to be hypertrophic 
and under high levels of oxidative stress due to increased activity of p27, a cell cycle 
inhibitor protein [74]. Upregulation of p27 activity has been associated with 
glomerulonephritis and renal damage, which was characterized by proteinuria, 
hyperfiltration, and renal hypertrophy. Hence, it is believed that the increased expression of 
p27 was a compensatory mechanism to stabilize the podocyte cell [74].  
 
Impacts of nephropathy on vitamin D homeostasis 
One of the more common nutritional deficiencies often seen in T2D patients is 
vitamin D deficiency. As the kidney plays a major role in maintaining vitamin D status and 
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activation of 25-hydroxycholecalciferol (25D) to 1,25-dihydroxycholecalciferol (1,25D), it is 
not surprising that damage of podocytes has been shown to accelerate the excretion of 
vitamin D metabolites in ZDF [79] and streptozotocin (STZ)-induced T1D rats [80]. These 
observations can be explained, at least in part, by increased filtration of vitamin D binding 
protein complex and compromised reabsorption by the proximal tubule [79, 80]. 
Furthermore, in vitamin D receptor (VDR)-null mice, accumulation of extracellular matrix 
proteins and pro-inflammatory as well as fibrogenic factors, was observed in the kidney [81, 
82], indicating that VDR signaling could be protective against renal fibrogenesis that is 
mediated by pro-inflammatory cytokines [82]. The evidence of VDR as a renoprotective 
factor was strengthened by additional studies in which VDR agonists, such as paricalcitol and 
calcitriol, reduced proteinuria in chronic kidney disease patients [83-85]. Moreover, in 
cultured podocytes, paricalcitol reduced renal inflammation by decreasing the expression of 
pro-inflammatory cytokines through the inhibition of NF-кB activity [83, 85]. Though the 
relationship between vitamin D and nephropathy has not been fully elucidated, links between 
the pathophysiology of diabetic nephropathy and vitamin D imbalance in T2D are becoming 
more numerous. Hence, this research area may prove to be critical in the development of 
dietary strategies that can prevent complications associated with diabetes.   
 
Impacts of nephropathy on the renin-angiotensin system 
The renin-angiotensin system (RAS) is a hormonal system that regulates arterial 
pressure, fluid balance, and electrolyte homeostasis of the cardiovascular, renal, and 
endocrine systems. Evidence suggests that the renoprotective effect of VDR could be 
mediated by RAS suppression, which seems plausible since the promoter region of renin is 
target of VDR [83, 86, 87]. When treated with an angiotensin II antagonist, interstitial 
fibrosis was prevented in VDR-null mice while paricalcitol, a VDR agonist, halted intrarenal 
RAS activation in an animal model of chronic kidney disease [88]. Collectively, these studies 
suggest that RAS plays a critical role in the prevention of nephropathy through VDR 
signaling, where low levels of circulating vitamin D may enhance RAS activity, which in 
turn could augment the progression of renal injury.  Chronic hyperglycemia has been shown 
to activate the intrarenal RAS, independent of systemic RAS activity, by stimulating the 
synthesis of intrarenal renin and angiotensin II, which are the pro-inflammatory factors that 
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promote vascular dysfunction, insulin resistance, and oxidative stress in experimental models 
of kidney disease [86, 89-92]. In support of these observations, Sharma et al [93] showed that 
chronic elevation of intrarenal angiotensin II caused proteinuria and glomerulosclerosis 
whereas treatment with Captopril, an angiotensin-converting enzyme inhibitor (ACEi), 
reversed the symptoms of diabetic nephropathy [93]. The mechanism responsible for these 
findings could involve the up-regulation of nephrin activity following the reduction of 
angiotensin II in diabetic nephropathy [94]. Nephrin is a slit diaphragm-associated protein 
that is necessary for maintenance of the renal filtration barrier. A reduction in nephrin was 
associated with proteinuria in patients with nephrotic syndrome [95-97] and treatment with 
angiotensin II antagonists preserved glomerular nephrin expression and prevented renal 
injury [94, 96, 98]. Therefore, changes in nephrin expression during the progression of 
diabetes suggest that podocyte structure alteration could be an early event in the development 
of diabetic nephropathy. Yet, not only was it observed that a blockade of the RAS restored 
nephrin expression, but down-regulation of the RAS was also associated with an increase in 
plasma adiponectin in patients with metabolic syndrome and type 2 diabetes [99-101]. 
Adiponectin is an adipokine primarily secreted by the adipocytes. In addition to being an 
insulin sensitizer, adiponectin is also known to have anti-inflammatory properties [102, 103]. 
Adiponectin has been shown to inhibit NF-kB activity and suppress production of both TNF-
α and IL-6, which are pro-inflammatory cytokines in adipocytes that tend to be elevated in 
obesity and insulin resistance [22]. Because the use of ACEi has been shown to improve 
insulin sensitivity and attenuate the development diabetic nephropathy [104-107], this 
suggests that adiponectin can play a major part in the regulation of RAS activity. In fact, 
adiponectin-knockout mice exhibited albuminuria and reduced podocyte permeability [108]. 
When adiponectin was administered exogenously, it delayed the progression of nephropathy 
in diabetic mice and attenuated renal oxidative stress via an angiotensin II-mediated pathway 
[109-111], suggesting that suppression of angiotensin II and key components of RAS may be 
signaled by adiponectin.  
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Vitamin D Status 
The biosynthesis and bioavailability of vitamin D can be affected by several factors. 
These factors include exposure to UVB radiation, obesity, gastrointestinal disease, and 
kidney disease [112]. Vitamin D status, as classified by the Institute of Medicine (IOM), is 
based on circulating 25D concentrations. Individuals can fall into four categories with respect 
to vitamin D status: deficiency, insufficiency, adequacy, and toxicity (Table 1) [113]. The 
dietary reference intake (DRI) requirement for vitamin D, which was set at 600 IU/d, was 
established for healthy populations based on bone health outcome because poor vitamin D 
status can lead to rickets, osteomalacia, calcium malabsorption, reduced bone mineral 
density, impaired muscle function, and elevated parathyroid hormone (PTH) levels [114-
116]. Thus the goal of the DRI for vitamin D was that this intake would help ensure that 
serum 25D levels would be maintained at 40 nmol/L, which in theory would prevent such 
complications. Yet, the recommended intake may vary based on the individual. Factors such 
as age, pregnancy, and lactation also need to be considered [113]. According to the Center 
for Disease Control, at least 32% of the US population aged one year of age and older are 
either vitamin D insufficient or deficient (serum 25D between 25 –  49.9 nmol/L and less 
than 25 nmol/L, respectively) [117]. Compromised vitamin D status is not limited to the 
United States, as similar observations have been found across numerous populations [115, 
116, 118-120]. There is emerging evidence suggesting that suboptimal serum levels of 25D 
increases the risk of chronic diseases unrelated to bone health, such as diabetes [119, 121], 
cancer [122-124], and autoimmune diseases [125, 126]. In order to reach the optimal level of 
25D (50 nmol/L or above), an average adult needs to consume between 2000-5000 IU 
Table 1. Vitamin D status based on serum 25D concentrations* 
 
Serum 25D concentrations  
Vitamin D Status nmol/L ng/mL 
< 30 < 12 Deficiency 
30 – 50 12 – 20 Insufficiency or inadequate for bone and overall 
health  
>50 >20 Adequate for bone and overall health   
>125 >50 Toxicity  
*Adapted from Institute of Medicine (IOM) [113] 
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vitamin D/day [127, 128], which is 5-fold higher than the recommended daily allowance 
(RDA). In addition, the RDA for vitamin D does not account for vitamin D requirements in 
specific groups that exhibit a higher prevalence of vitamin D deficiency and/or insufficiency 
such as those with chronic kidney disease or other forms of nephropathy. Thus, re-evaluation 
of the RDA for vitamin D may be needed to ensure that requirements meet the needs for all 
individuals, due to the many factors that can influence vitamin D status mentioned above. 
The issue of vitamin D toxicity is currently a topic of debate. Studies [129, 130] have 
reported that 10,000 IU/d of vitamin D for 4 months did not produce any toxicity. Others 
have also indicated that consumption of 10,000 IU of vitamin D per week was associated 
with a reduction in falls and fractures in the elderly [131], and monthly dosing of 50,000 IU 
of vitamin D corrected vitamin D deficiency in elderly patients [132]. While many have 
suggested that there is a need to increase the RDA of vitamin D for the prevention of chronic 
disease, research on vitamin D supplementation and its impact on health is controversial. 
Even at 4800 IU/day of vitamin D3 supplementation, calcium absorption as well as serum 
25D and 1, 25D concentrations in post-menopausal women were not significantly improved 
compared to the placebo, unless they were severely vitamin D deficient [133]. The 
contradictory results yielded from the aforementioned vitamin D studies may be due to lack 
of consistency in their experimental design because long-term effects and repeated dosing 
regimens were not accounted for. Considering the potential purported benefits of vitamin D, 
optimization of vitamin D status for the prevention of chronic diseases is an area that is under 
intense investigation.    
 
Vitamin D Biosynthesis and Metabolism 
Vitamin D is unique among nutrients because it is readily synthesized by the skin when 7-
dehydrocholesterol is exposed to UVB radiation (280 – 315 nm). This followed by the 
generation of pre-vitamin D3, which is further isomerized to vitamin D3. Once vitamin D3 is 
formed in the epidermis, it is quickly absorbed in the dermal capillary bed and released into 
circulation, which then is converted into active metabolites or stored in the adipose tissue. 
[134].  The serum half-life of vitamin D3 is approximately 15 days, but storage in the 
adipocytes can prolong the total body half-life to about two months [135, 136]. In addition to 
sunlight exposure, vitamin D2 and vitamin D3 can be acquired through the diet. Examples of 
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vitamin D3-rich foods are cod liver oil, salmon, and egg yolks. Vitamin D2 is found in plant 
sources such as mushrooms. Hereafter, both vitamin D3 and D2 will be referred to 
collectively as vitamin D, unless otherwise specified. Upon consumption, dietary vitamin D 
is handled along with dietary lipids and incorporated into micelles prior to absorption by the 
intestinal mucosa via passive diffusion. Once absorbed by mucosal cells, vitamin D is 
packaged into chylomicrons along with other lipids and lipid-soluble vitamins, and released 
into the lymphatic system and then the blood. Circulating vitamin D, acquired either through 
endogenous synthesis or from the diet, is then transported to the liver via DBP and 
Fig. 1. Vitamin D Metabolism. Diagram adapted from 
Tsiaras et al [106]. 
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hydroxylated at the C-25 side chain by the vitamin D-25-hydroxylase (CYP27A1) for 
production of 25D, which again binds to DBP and circulates to the kidney [112, 137] (Fig. 
1). Kidney is the major synthesis site of the active vitamin D hormone, 1,25D. Before 25D 
can be activated in the kidney, it must enter renal proximal tubules by receptor-mediated 
endocytosis, which requires the endocytic partners, megalin and cubilin (Fig. 2). Megalin and 
cubilin bind to 25D-DBP complex at high affinity with the help of intracellular adaptor 
proteins, such as disabled-2 (Dab2), and internalize it into the proximal tubule to form 
endosomal vesicles [138, 139]. Here, 25D can then either be converted to its active form 
1,25D by the CYP27B1 enzyme (25-hydroxycholecalciferol-1α-hydroxlase) or reabsorbed 
into circulation. The role of megalin, DBP, and CYP27B1 in vitamin D activation has been 
defined in studies involving megalin- and CYP27B1-deficient mice [138, 140-142], which 
developed severe vitamin D deficiency and bone malformations. Moreover, DBP-null mice 
exhibit decreased serum 1,25D levels [143]. With respect to the metabolism of vitamin D in 
the kidney, not only is the kidney crucial for the production of 1,25D, it is also responsible 
for vitamin D catabolism, which is mediated by another mitochondrial P450 enzyme, 
CYP24A1 (25-hydroxycholecalciferol-24-hydroxylase). CYP24A1, as opposed to CYP27B1, 
facilitates the catabolism of 25D or 1,25D to calcitronic acid via series of hydroxylation 
reactions at C-24 [144] for vitamin D inactivation and excretion. The process also decreases 
the availability of 25D to CYP27B1, and hence suppresses its activation [145]. Due to its 
extremely high potency, production of 1,25D promotes its own catabolism by 
transcriptionally regulating CYP24A1. 1,25D concentrations are also influenced by several 
additional factors, such as PTH, serum calcium and phosphorus concentrations, and 
fibroblast growth factor 23 (FGF-23), a phosphaturic factor synthesized in the osteoblastic 
cells that is known to regulate phosphate homeostasis in response to 1,25D [146, 147] When 
1,25D levels are elevated, transcription of FGF-23 in the kidney is enhanced to stimulate the 
expression of CYP24A1 and simultaneously inhibit the activity of CYP27B1. On the other 
hand, low levels of 1,25D repress CYP24A1 and activate CYP27B1 expression to enhance 
the production of 1,25D, which subsequently provides a feedback inhibition of FGF-23 and 
PTH production [147].    
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Molecular Action of Vitamin D 
 The actions of 1,25D are mediated by the membrane-bound vitamin D receptor 
(VDR), a nuclear receptor that belongs to a subclass of nuclear transcription factors. Upon 
the binding of 1,25D, VDR translocates from the cytosol to the nucleus where it is 
phosphorylated and forms a heterodimer with the retinoid X receptor (RXR). The VDR-RXR 
heterodimer complex can then binds to vitamin D response elements (VDRE) and induce 
transcription of genes [146, 148]. There are two major functional units of the human VDR, 
the N-terminal zinc finger DNA-binding domain and the C-terminal ligand-binding domain. 
Gene expression mediated by 1,25D and VDR is initiated by the RXR heterodimerization. 
The presence of liganded VDR changes the position of H12 at the C-terminus of VDR for 
coactivator binding, which further promotes histone acetylation and chromatin remodeling 
[146]. Transcriptional regulation by 1,25D-bound VDR involves a number of steps at the 
level of the gene. Many factors are recruited to the transcription site upon the formation of 
the VDR-RXR heterodimer such as TATA binding protein associated factors, D-receptor 
interacting proteins (DRIP), and when coupled with RNA polymerase II as well as other 
nuclear receptor coactivators, this complex will facilitate RNA processing during target gene 
transcription [137, 146]. VDR can also down-regulate the transcription of various genes. 
Repression of gene transcription by VDR-RXR is introduced by the docking of the VDR-
RXR complex on a negative 
VDRE that binds to a co-repressor 
and alters the chromatin structure 
via histone deacetylation and 
demethylation of histones [137, 
146]. In addition, non-genomic 
actions of VDR have been 
identified and they are stimulated 
by the activation of plasma 
membrane receptors and second 
messengers such as MAPK, 
cAMP, and phospholipase C [137]. 
The discovery of non-genomic 
Fig. 2 Endocytic uptake of vitamin D-DBP 
complex in the proximal tubule cells. Diagram 
adapted from Kaseda et al [133]. 
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activity of 1,25D has also led to the extension of research on vitamin D and its metabolites 
beyond bone health, especially after CYP27B1 was discovered in extra-renal sites such as 
skin, macrophages, colon, breast, prostate, pancreas, and vascular epithelial cells [149-151]. 
On that note, low circulating 25D concentrations have been associated with diseases such as 
cancer, diabetes, and autoimmune diseases, in sites that express CYP27B1.  
 
Vitamin D and calcium homeostasis 
The role of vitamin D in calcium and phosphorus homeostasis is well established and 
thus vitamin D status must be maintained for optimal bone mineralization. Studies have 
shown that VDR null mice developed hypocalcemia, secondary hyperparathyroidism, 
hyperphosphatemia, all which can contribute to the development of osteopenia [152, 153]. 
However, these phenotypic characteristics can be prevented in these mice by feeding a high 
calcium diet in combination with lactose, which enhances the solubility of calcium [137, 
144]. The efficiency of calcium absorption is dependent on the serum calcium 
concentrations. In times of high calcium intake, the majority of calcium absorption involves 
the transport of calcium ions between intestinal tight junctions in the duodenum and jejunum, 
a process called paracellular diffusion [144, 154]. In times of low calcium intake, the 
majority of calcium ions are transported transcellularly through mucosal cells via a vitamin 
D- and energy-dependent pathway. The transcellular transport of calcium across the 
epithelial cell is mediated by several vitamin D-dependent transporters including the apical 
calcium channel, TRPV6, which binds luminal calcium ions and transfers them to calbindin 
for translocation to the basolateral membrane for release into circulation. Calcium 
homeostasis is a tightly coordinated by the actions of several hormones, which include PTH, 
1,25D, and calcitonin [144]. Under hypocalcemic condition, the parathyroid gland is 
stimulated to secrete PTH. PTH in turn travels to multiple sites simultaneously to increase 
calcium concentrations by stimulating renal calcium reabsorption, intestinal absorption of 
calcium phosphate, as well as calcium and phosphate release via bone resorption [144]. 
During hypercalcemia, 1,25D signals its own catabolism via CYP24A1 and suppresses the 
renal hydroxylation of 25D [144, 155].   
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Vitamin D and diabetes mellitus 
Current literature has provided rather convincing evidence that vitamin D plays a 
pivotal role in the prevention of pancreatic beta cell destruction and maintenance of glucose 
metabolism. Based on cross-sectional studies, low vitamin D status has been closely 
associated with impaired insulin sensitivity, which characterizes T2D [118, 120, 156-158]. 
However, more work is needed to further elucidate mechanisms by which vitamin D exerts 
its actions with respect to glucose metabolism. Compared to populations with lower BMI, 
those who are overweight and obese are more prone to vitamin D deficiency or insufficiency 
[119, 120, 159], which may place them at higher risk for T2D due to the potential role of 
vitamin D in regulating glucose homeostasis. Our laboratory is among those that have 
demonstrated that hyperglycemia was associated with excessive excretion of vitamin D 
metabolites [79, 80] and shedding of megalin into the urine [160].  Not surprisingly, a 
disruption of vitamin D homeostasis during the progression of diabetes was reported in these 
studies. This is further supported by a clinical study that showed that urinary loss of DBP 
contributed to vitamin D deficiency in T1D patients [161]. Hence, observations such as these 
may explain, at least in part, why low vitamin D status is common in diabetic patients. 
 In a study with pre-diabetic patients, vitamin D deficiency exacerbated insulin 
resistance [156]. This suggests that vitamin D might have a functional role in modulating 
glucose homeostasis. In line with this concept, numerous observational studies reported that 
improvement of vitamin D status via supplementation enhanced insulin sensitivity and 
reduced fasting blood glucose levels in type 2 diabetic patients [159, 162, 163]. Additionally, 
Mitri et al. [163] reported that vitamin D supplementation with up to 2000 IU/d improved 
beta cell function and attenuated hyperglycemia in type 2 diabetics. Furthermore, 
supplementing diabetic patients with 4000 IU/day of vitamin D improved insulin sensitivity 
in obese individuals [159] and high dose vitamin D supplementation (50,000 IU/wk) 
improved fasting plasma glucose and insulin sensitivity in T2D patients [162, 164].  
The reasoning behind the investigation of the role of vitamin D in the promotion of 
insulin secretion includes the presence of VDR [165, 166] and 1-α hydroxylase [167] in beta 
cells. In mice lacking VDR, mRNA expression of insulin as well as serum insulin 
concentrations were lower and response to an oral glucose tolerance test was less robust 
compared to wild-type mice [166]. Similar observations have been reported in studies 
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involving rats fed a vitamin D deficient diet. In these studies, insulin secretion and glucose 
tolerance were impaired by vitamin D deficiency and vitamin D repletion normalized insulin 
secretion [168-170]. The underlying mechanism by which vitamin D promotes insulin 
secretion by beta cells is still lacking. Gysemans et al. [169] reported that treatment with 
1,25D prevented the incidence of diabetes in NOD mice, a model of T1D, through the 
suppression of pro-inflammatory cytokine expression, such as IL-1beta and IL-15, in beta 
cells, along with the amelioration of insulitis. However, when insulitis was already present 
(late intervention at 14 wk of age), treatment with 1,25D failed to prevent diabetes in NOD 
mice. This further indicates that the protective effect of 1,25D against beta cell destruction is 
limited when they are already infiltrated with immune cells. As mentioned earlier, this is in 
contrast to its preventative effect during the early stage of insulitis. Similarly, others have 
reported that insulin signaling was modulated by VDR via its action on the glutamate 
receptor or the AMPA receptor [170] and pancreatic RAS signaling [171], as these signaling 
pathways were altered under hyperglycemic state. However, supplementation with vitamin D 
normalized the expression of the pancreatic AMPA receptor and RAS components, as well as 
restored calcium-mediated insulin secretion independent of hyperglycemia [170, 171].  
Despite the reported benefits of vitamin D with respect to regulation of glucose 
homeostasis, the specific relationship between vitamin D deficiency and T2D remains 
unclear. In children (birth to 6 years of age) and adolescents (~18 years of age) with T1D, the 
presence of vitamin D deficiency or insufficiency did not correlate with the progression of 
diabetes [172, 173].  Moreover, in recent reviews, it was concluded that current available 
randomized controlled and longitudinal studies have not provided sufficient evidence to 
support the notion that vitamin D supplementation improves hyperglycemia and insulin 
sensitivity in patients with type 2 diabetes [174, 175]. Although high dose vitamin D 
supplementation corrected vitamin D status in prediabetes and diabetes, increased vitamin D 
status was not associated with insulin sensitivity or circulating glucose concentrations [176, 
177]. Because long-term interventions are difficult to conduct with vitamin D, since it is 
believed to have the strongest impact on long-latency diseases, the role of vitamin D in 
improving glucose homeostasis over the long term remains unclear. Furthermore, because 
most clinical trials that investigated vitamin D’s impact on diabetes involved patients with 
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pre-existing diabetes, understanding the role of vitamin D in the prevention of diabetes or 
related complications remains elusive. 
 
Resistant Starch 
Dietary fiber is a class of non-digestible carbohydrates that includes lignin, cellulose, 
oligosaccharides, inulin, and various forms of resistant starch. The various physiological 
functions of different fibers depend on their structural properties. Viscous or soluble fiber, 
for example, can delay gastric emptying and lower postprandial glucose concentrations, 
while insoluble fibers can help to improve gastric motility and usually have a laxative effect 
[178].  It is recommended that total fiber intake (adequate intake, AI), according to the DRIs, 
should be 25g/ d for women and 38 g/d for men ages 19 – 50 based on median energy intake 
(14g of fiber/1000 kcal) [178]. The consumption of fiber in the U.S. is a concern, since 
Americans, regardless of gender, only consume an average of 15g/d of fiber, which is well 
below the AI [179]. Because low glycemic index diets and increased consumption of fiber-
containing foods have been shown to improve symptoms of obesity-related complications, 
such as diabetes and cardiovascular diseases [180-182], it has been generally accepted that 
replacing highly digestible starch with dietary fiber is beneficial with respect to weight and 
blood glucose management. Though many dietary fibers have received significant attention, 
with respect to their health benefits, resistant starch (RS) in particular has recently received a 
great deal of interest. RS is a non-viscous fermentable fiber that is partially indigestible and 
is classified into four categories [183]:  
 
1. Type 1 (RS1): Physically inaccessible starch 
RS1 is found in whole or partly milled grains and seeds. The intact cell walls that 
surround starch granules retard enzymatic hydrolysis of amylose and amylopectin in 
these products.   
 
2. Type 2 (RS2): Resistant starch granules  
The natural form of RS2 is usually found in raw starch, such as unripe banana and 
potato starch. However, RS2 found in these sources can be gelatinized after heating 
and thus become digestible due to increased access of amylases to starch. In contrast, 
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high-amylose maize (HAM), which is high in RS2 due to a mutated gene on the 
starch branching enzyme to produce high amylose content, possesses higher 
gelatinization temperature due to a strong interaction between amylose chains [184]. 
Because of these properties, RS2 from HAM is able to maintain its resistance against 
enzymatic hydrolysis even after heating.     
 
3. Type 3 (RS3): Retrograded starch 
Retrograded starch is mostly found in starchy food products that have been cooked 
then cooled, such as potatoes, sweet potatoes, and beans. This is mainly due to the 
dissociation of crystalline structures in both amylose and amylopectin upon heating of 
a native starch. On cooling, the crystalline structures rearrange through the formation 
of double helices to yield a much more stable structure (RS3). RS3 has a 
gelatinization temperature that is highly resistant to heat and enzymes [185]. 
However, unlike RS2, the retrogradation process may be reversible as reheating the 
starch may again promote gelation and reduce crystallinity of starch [185].   
 
4. Type 4 (RS4): Chemically modified starch  
RS4 is formed by the chemical modification of starch with molecules such as acetyl 
group, octenyl group, or hydroxylpropyl groups to prevent starch granules from 
enzymatic hydrolysis [186, 187]. Cross-linkage is another common modification 
method in which the hydrogen bonds in starch molecules are strengthened by a cross-
linking agent. This cross-linking prevents starch granules in RS4 from swelling and 
hydrolysis [188].  
 
5. Type 5 (RS5): Amylose-lipid complex starch 
Production of RS5 involves the addition of free fatty acids to high-amylose maize. 
The amylose-lipid interaction leads to the formation of helical complex structure that 
are resistant to swelling and enzyme hydrolysis [189].    
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Resistant starch and glucose homeostasis 
 The number of metabolic syndrome cases across the world has grown at an alarming 
rate. While treatment options are available to better control metabolic syndrome, the most 
effective long-term interventions appear to be lifestyle modifications such as dietary changes 
and increased physical activity. The acceptable macronutrient distribution range for 
carbohydrate is between 45 – 65% of the total daily energy intake [178]. However, the type 
of carbohydrate consumed has a profound impact on glycemic response. Silva et al [180] 
demonstrated that high glycemic index and low fiber breakfast markedly increased 
postprandial plasma glucose and insulin concentrations in T2D patients. Similarly, animal 
studies demonstrated that glucose- and amylopectin-fed animals developed insulin resistance 
at an earlier age compared to rats receiving amylose, which has a lower glycemic index [190, 
191]. Thus, consumption of non-digestible fibers such as resistant starch (RS) and 
oligosaccharides, due to their lower glycemic properties, is recommended for better 
management of T2D. With respect to RS, studies involving feeding of RS-containing 
products, such as high-amylose rice and cornstarch, to diabetic animals have consistently 
shown that these products lower the postprandial glycemic response as well as circulating 
triglyceride, and cholesterol levels [192, 193]. Interestingly, it was recently shown that 
administration of RS to diabetic rats optimized lipid oxidation pathways, glycogen synthesis, 
and insulin sensitivity while the expression of genes central to fatty acid and triglyceride 
synthesis, such as the sterol regulatory element-binding protein-1c (SREBP-1c), an insulin-
regulated protein that is essential for transcriptional regulation of glycolytic and lipogenic 
genes, was attenuated [194]. This suggests that the improved postprandial insulin and glucose 
response by RS is driven by the regulation of glucose and lipid metabolism-related genes. 
Another putative mechanism may involve the secretion of gut hormones associated with the 
regulation of postprandial satiety, such as glucagon-like peptide-1 (GLP-1) and peptide YY 
(PYY), which were secreted in response to administration of short chain fatty acids (SCFA), 
fermentation products of RS [195, 196]. Studies by Keenan et al. [195] demonstrated that RS 
lowered abdominal fat and energy intake in rats, which correlated with higher levels of 
plasma GLP-1 and PYY, as well as an elevation of PYY gene expression in the cecum and 
large intestine. These observations are supported by other studies that have shown that RS 
reduced adipocyte size [197] and weight gain in obese prone rats [198]. When evaluating the 
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literature with respect to the use of RS for management of adiposity, the source of RS 
appears to be critical when interpreting results from both animal and human studies. In a 24-
week feeding study with high-amylose RS2 starch and RS4 starch containing 
hydroxypropylated distarch phosphate, obese mice fed the RS4 diet gained less weight and 
exhibited lower adiposity accumulation as well as increased energy expenditure compared to 
the RS2-fed obese mice [199]. It is not well understood why the phenotypic responses were 
difference between RS2- and RS4-treated mice since the bioavailability of both starches were 
equivalent [199]. It is possible that RS4 may have affected endogenous nutrient transport 
differently than RS2 as these starches may alter gastric emptying to a different degree. This is 
further supported by the observation where the transport of fatty acids from the lumen to the 
jejunum was significantly lower in HFD-induced obese mice treated with RS4 compared to 
RS2-fed obese mice, which indicates that RS4 may have reduced intestinal lipid absorption 
[199].    
While solid evidence with respect to the beneficial effect of RS has been reported in 
animal models of obesity and diabetes, results from human studies have been inconsistent 
(Table 2). This could be due to the high variability of RS dosage used for these studies. 
Estimation of resistant starch intake based on 1999 – 2002 NHANES 24-hour dietary recall 
data has demonstrated that the average consumption of RS among Americans aged 1 year 
and older is approximately 5 g/d [200]. However, according to the aforementioned studies, 
the minimal effective daily intake of RS for the prevention of obesity-related diabetes 
appears to be greater than 5 g/d [181, 201-203]. Moreover, most dietary interventions that 
yielded positive metabolic outcomes have included RS at a dosage (7 g – 48 g/d of RS) that 
exceeds what is consumed by the US population (Table 2). Nonetheless, clinical studies with 
healthy subjects have generally demonstrated that RS feeding resulted in an improved 
postprandial glycemic response [202-206] compared to obese or diabetic individuals [182, 
207, 208]. The differences observed in these studies could be due to the variability in dosage 
and type of fiber used. Moreover, as most of this work was done by feeding RS or RS-
containing diets acutely, contradictory results and lack of long-term studies using dietary RS 
indicates that the role of RS in benefiting health in overweight and obese individuals requires 
further investigation.  
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Table 2. Human interventional studies investigating the effect of resistant starch against glucose metabolism.  
 
Author, 
Country 
Baseline 
Characteristics   
Study Design  Dose  Impact on glucose and 
insulin outcomes  
Other observed 
outcomes 
De Roos et al., 
1995 (The 
Netherlands) 
[229]  
 
n = 24, male, 
healthy individuals  
-Single-blind, 
randomized crossover 
study receiving either 
glucose, high-
amylose corn starch 
(RS2), or extruded 
and retrograded high-
amylose corn starch 
(RS3) for 1 wk 
 
RS2 or RS3 at 30 
g/day  
-RS2 lowered appetite 
score compared to RS3  
-RS3, but not RS2, reduced 
insulin secretion  
 
Noakes et al., 
1996 
(Australia) 
[230]  
n = 23 (10 female, 
13 male), 
overweight (BMI 
29 ± 2), aged 51 ± 
7 
-12-wk dietary trial, 3 
phases, each phase 
consisted of 4 wks 
(no washout period) 
 
-3 treatments (high-
amylose diet, oat bran 
diet, and low-
amylose diet) 
 
-High-amylose 
starch at 50 g/d for 
female and 74g/d 
for male 
-Oat bran at 87 g/d 
for female and 121 
g/d for male 
-Fasting glucose was 
higher with oat bran 
compared to high- or low-
amylose diet  
-Postprandial insulin was 
lowered with high-amylose 
diet compared to low-
amylose diet 
-Plasma 
triacylglycerol 
was lowered 
with oat bran 
diet but not with 
high- or low-
amylose diet  
 
Robertson et 
al., 2003 (UK) 
[231] 
n = 10 (6 female, 4 
male), aged 47.2 
yrs, BMI 26.9, 
healthy subjects 
-Single-blind 
crossover study  
 
-High RS diet or Low 
RS diet for 24 h 
-High RS diet 
containing 100 g of 
Hi-Maize 260 ® 
(60 g of RS and 40 
g of rapidly 
digestible starch) 
-Low RS diet  
-High RS, but not Low RS, 
lowered postprandial 
insulin concentrations 
 
-No effect on 
plasma 
triacylglycerol 
2
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 Table 2. Continued 
 
Author  Baseline 
characteristics   
Study Design  RS Dose  Impact on glucose and 
insulin outcomes  
Other observed 
outcomes 
… 
Robertson et 
al., 2003 
(UK) [203] 
  containing 40 g of 
waxy-maize starch 
(40 g of rapidly 
digestible starch) 
 
  
Higgins et 
al., 2004 
(USA) [231] 
n = 12 (7 male, 5 
female), aged 33 ± 
5 yrs, normal 
glucose tolerance, 
BMI 24.7 ± 2.4 
 
-Subjects received 4 
meals at various 
doses of RS at 4 wks 
apart 
 
0% , 2.7%, 5.4%, 
and 10.7% RS2 in 
the form of high-
amylose maize 
starch  
-No effect on fasting or 
postprandial insulin and 
glucose 
 
-5.4% RS 
increased lipid 
oxidation 
compared to 
controls 
Robertson et 
al., 2005 
(UK) [202] 
n = 10 (6 female, 4 
male), aged 48.5 ± 
3.4 yrs, BMI 23.4 ± 
1.4 
-Single-blind, 
crossover study for 
12 wks  
 
-RS or corn starch for 
4 wks, with 4 wks of 
washout period  
 
Hi-Maize 260 ® at 
50g/day (30 g of 
RS2 and 20g of 
rapidly digestible 
starch) 
-Improved insulin 
sensitivity  
-Increased muscle glucose 
tolerance  
-Lowered NEFA 
and glycerol in 
subcutaneous 
abdominal 
adipose tissue  
 
Behall et al., 
2006 (US) 
[232] 
n = 20 (10 
overweight women 
with BMI 30.4; 10 
normal weight 
women with BMI 
22), healthy, aged 
43.3 yrs 
-High-amylose corn 
starch (HAM) with or 
without beta glucan  
 
 
HAM with 5.06 g 
of RS/100 g of 
muffin with either 
0.26, 0.68, or 2.3 g 
of beta-glucan/100 
g muffin 
 
-Combination of high-
amylose starch and beta-
glucan  improved 
postprandial plasma 
glucose and insulin in both 
normal and overweight 
women 
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Table 2. Continued 
 
Author  Baseline 
characteristics   
Study Design  RS Dose  Impact on glucose and 
insulin outcomes  
Other observed 
outcomes 
Al-Tamimi et 
al., 2009 
(USA) [204] 
 
 
n = 13, healthy 
individuals (7 
females, 6 males), 
aged 27±5 yrs, BMI 
25± 3  
 
 
-Randomized 
crossover design 
-3 trials to consume 
cross-linked RS4 bar, 
glucose beverage, 
and wheat-containing 
bar; washout period 
for 7 d   
 
80 g cross-linked 
RS4/d (~14 g RS/d) 
-RS4 attenuated 
postprandial glucose and 
insulin response  
 
 
Bodinham et 
al, 2010 
(UK) [233] 
n = 20, healthy 
individuals, aged 
19-31 yrs, BMI 
23.2 ± 0.65 
-Single-blind, 
randomized crossover 
study  
-RS or placebo 
supplement within 
the test breakfast and 
lunch (washout 
period of 7 d) 
 
80 g Hi-Maize 
260® providing 48 
g of RS (24 g RS 
with lunch, 24 g RS 
with dinner)   
-No changes in plasma 
glucose  
-Post-prandial insulin 
response was lowered  
 
-Reduced energy 
intake  
-No difference in 
subjective 
appetite scores  
 
Johnston et 
al., 2010  
(UK) [206] 
n = 20 (8 female, 
12 male), aged 50.1 
± 4.05 (placebo) 
and 45.2 ± 3.55 
(RS), BMI 30.4 ± 
1.15 (Placebo), and 
31.3 ± 1.7 (RS) 
 
-Single-blind, 
randomized parallel 
study for 12 wks 
 
Hi-Maize 260® 
providing 40 g/d 
RS2 and 27 g/d of 
rapidly digestible 
starch 
-Improved insulin 
sensitivity but not fasting 
insulin and beta cell 
function 
-Insulin sensitivity was 
inversely correlated with 
waist circumference 
 
-No changes in 
body weight, fat 
storage in 
muscle, liver,  
visceral fat, 
vascular 
function, or 
inflammatory 
markers 
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Table 2. Continued  
 
Author  Baseline 
characteristics   
Study Design  RS Dose  Impact on glucose and 
insulin outcomes  
Other observed 
outcomes 
Ble-Castillo 
et al., 2010 
(Mexico) 
[234] 
n = 28 with T2D (4 
male, 24 female), 
aged 51.7 ± 5.6, 
BMI 34.89 ± 2.32, 
fasting glucose 
145.94± 104.17 
mg/dL, fasting 
insulin 14.1 uU/mL 
Crossover design 
with 2 4-wk 
experimental periods 
receiving native 
banana starch (NBS) 
and soya milk  
 
24 g of NBS (8.16 
g of RS) dissolved 
in 240 mL water  
-Reduced body weight and 
BMI  
-Reduced fasting insulin 
levels 
-Insulin sensitivity was 
improved compared to 
baseline, but not when 
compared to the control 
group  
 
 
Penn-
Marshall et 
al., 2010 
(USA) [201] 
n = 17 (8 male, 9 
female), aged 36.6 
± 1.55 yrs, African 
American, T2D, 
BMI 37.7 ± 2, 
fasting glucose 
99.86± 2.63 mg/dL  
 
-Double-blind, 
crossover study with 
2 wks of washout 
period 
-6-wk feeding trial  
12.39g of Hi-Maize 
260® (in the form 
of bread loaf) with 
10.17 g of RS/100 g 
of bread 
-No change in blood 
glucose, insulin, or CRP 
levels  
-HOMA-IR was 
normalized by RS but was 
not significantly different 
from control 
 
Bodinham et 
al., 2012 
(UK) [205] 
n = 12 (8 male, 4 
female), aged 37 ± 
4 yrs, BMI 28.2 ± 
0.4 (overweight), 
without T2D or 
insulin resistance  
-Single-blind, 
randomized crossover 
study for 4 wks with 
a 4 wk washout 
period between 
interventions 
 
 
67 g Hi-Maize 
260® providing 40 
g RS2 from maize 
(HAM-RS2) 
 
-Improved first-phase 
insulin response  
 
 
 
 
3
0
 
 
31 
 
 
 
Table 2. Continued  
 
Author  Baseline 
characteristics   
Study Design  RS Dose  Impact on glucose and 
insulin outcomes  
Other observed 
outcomes 
Maki et al., 
2012 (USA) 
[181] 
n = 33 (11 male, 22 
female), aged 49.5 
± 1.6, BMI 30.6 ± 
0.5 
-Double-blind, 
randomized crossover 
study for 4 wks, with 
3 wks of washout 
periods between RS 
or corn starch diet 
intervention 
 
Hi-Maize 260® at 
60% RS (HAM-
RS2) given at 15g/d 
or 30g/d  
-RS improved insulin 
sensitivity with both 
dosages, but was only 
observed in men, not 
women 
 
 
Kwak et al., 
2012 (Korea) 
[235] 
n =85, 47 male, 38 
female, aged 49.4 ± 
1.74 yrs (placebo) 
and 51.7 ± 2.03 yrs 
(RS group), patients 
with impaired 
fasting glucose, 
impaired glucose 
tolerance, or newly 
diagnosed T2D 
 
First phase: 2-wk 
usual diet  
Second phase: 4-wk 
intervention with 
refined rice or RS-
containing rice   
Rice containing 6.5 
g/d of RS  
-Reduced fasting insulin 
and insulin resistance, 
postprandial glucose, and 
improved insulin 
sensitivity 
 
-Improved 
endothelial 
function with 
increased total 
nitric oxide and 
superoxide 
dismutase 
activity 
Klosterbuer 
et al., 2012 
(USA) [236] 
n = 20 (10 male, 10 
female), aged 29 ± 
8 yrs, BMI 23 ± 2  
-Double-blind, 
randomized crossover 
study receiving low-
(control) or high-fiber 
diet  
 
25 g of fiber from 
soluble corn fiber 
or resistant starch 
alone or in 
combination with 5 
g of pullulan 
 
-RS + pullulan reduced 
glucose and insulin 
-No effect on 
satiety or energy 
intake  
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Table 2. Continued 
 
Author  Baseline 
characteristics   
Study Design  RS Dose  Impact on glucose and 
insulin outcomes  
Other observed 
outcomes 
Lobley et al., 
2013 (UK) 
[208] 
n = 14, male, at 
least met three 
symptoms of 
metabolic 
syndrome  
 
4 periods of dietary 
intervention without 
washing period 
Period 1 (7 d):  
Maintenance diet 
with 5 g/d of RS, 
27 d/g of NSP  
Period 2 and 3 (21 
d): Randomized RS 
(25 g/d of RS, 16 
d/d of NSP) or NSP 
(41 g/d of NSP, 2.5 
g/d of RS) diet  
Period 4 (21 d):  
Weight loss high-
protein diet with 25 
g/d NSP and 2.9 g/d 
of RS 
 
-Addition of RS or NSP 
did not affect the glycemic 
control  
 
Bodinham et 
al., 2014 
(UK) [207] 
n  = 17 (12 male, 5 
female), well-
controlled T2D on 
anti-diabetic agents, 
aged 55 ± 2.4,  BMI 
30.6 ± 1.3, HbA1c 
levels of 46.6 ± 2 
-Single-blind, 
randomized crossover 
study for 12 wks with 
a 12-wks washout 
period between 
interventions 
 
67 g Hi-Maize 
260®providing 40 
g RS2 from maize 
(HAM-RS2) 
  
-No differences in fasting 
glucose, insulin, HOMA-B, 
and HbA1c 
  
-Lower NEFA 
concentrations 
but no 
differences in 
blood pressure 
and vascular 
functions 
-Lower fasting 
TNF-α 
concentrations  
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Table 2. Continued 
 
Author  Baseline 
characteristics   
Study Design  RS Dose  Impact on glucose and 
insulin outcomes  
Other observed 
outcomes 
Dodevska et 
al., 2015 
(Serbia) 
[182] 
 
n = 47, overweight 
and obese men and 
women, aged 45-
74, moderate 
physical activity for 
a minimum of 
4h/week 
 
 
-12 months under 
free-living condition 
(lifestyle 
intervention) 
-Subjects were 
instructed to follow a 
diet either high in 
fiber (Fiber group) or 
resistant starch (RS 
group) 
RS group:  
-Total fiber = 27.36 
g/d 
- Total RS = 14.72 
g/d 
 
Fiber group:  
-Total fiber = 27.44 
g/d 
-Total RS = 7.52 
g/d 
-Fiber-rich diet, but not 
RS-rich diet, improved 
glucose tolerance in 
overweight and obese 
individuals 
 
-Both treatments 
reduced body 
weight, BMI, 
and waist 
circumference 
-RS decreased 
total cholesterol 
and LDL, no 
change in HDL 
-Fiber increased 
HDL, no change 
in LDL or total 
cholesterol  
 
BMI: Body mass index; CRP: C-reactive protein; HAM: High-amylose maize; HbA1c: Hemoglobin A1c; HDL: High density 
lipoprotein; HOMA-IR: Homeostatic model assessment-insulin resistance; LDL: Low density lipoprotein; NBS; Native banana starch; 
NEFA: Non-esterified fatty acids; NSP: Non-starch polysaccharides; RS: Resistant starch; T2D: Type 2 diabetes; TNF-α: Tumor 
necrosis factor-α.    
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Short chain fatty acids  
It is known that SCFAs resulting from colonic microbial fermentation can serve as a 
local energy source for the host. The predominant SCFAs (detected at the highest 
concentration in mammalian distal small intestine and colon) produced by bacteria include 
butyrate, acetate, and propionate [209]. While butyrate is readily absorbed and utilized by 
colonocytes for energy, propionate and acetate that are transported into circulation can enter 
the TCA cycle and serve as a precursor for hepatic gluconeogenesis and lipogenesis [210]. 
SCFAs may also have a therapeutic value as they alleviated symptoms of type 2 diabetes in 
HFD-induced obese animals. Butyrate, for example, has been shown to enhance insulin 
sensitivity, glucose tolerance, and attenuate beta cell apoptosis in obese and diabetic animals 
when administered either intraperitoneally or orally ingested [211-213], possibly due to its 
role as a histone deacetylase inhibitor [211]. However, the mechanism by which SCFAs 
promote normal glucose homeostasis is not entirely clear. In in vitro studies, it was 
demonstrated that free fatty acid receptor-2 (FFAR2) is an endogenous transmembrane 
receptor for acetate and propionate; while the free fatty acid receptor-3 (FFAR3) is a 
membrane receptor for butyrate and acetate in vitro [214, 215]. Because FFAR2 and FFAR3 
are abundant in the intestinal L-cells, it is possible that SCFAs regulate intestinal secretion of 
GLP-1 and PYY and subsequently the regulation of glucose homeostasis through the 
activation of specific FFAR signaling to modulate L-cell activity [209, 216]. This is 
supported by a study conducted by Tolhurst et al. [209], in which FFAR2- and FFAR3-
deficient mice developed impaired glucose tolerance and decreased plasma insulin levels, 
both of which correlated with reduced circulating GLP-1. The role of FFAR2 and FFAR3 in 
energy and glucose homeostasis was further characterized in KO mouse models [216, 217]. 
Compared to wild type mice, FFAR3-KO mice presented marked weight loss and lower 
epididymal fat pad adiposity when raised conventionally or co-colonized with Bacteroides 
thetaiotaomicron and Methanobrevibacter smithii, prominent bacteria that are known to 
promote polysaccharide fermentation. However, the improvements on growth rate and 
adiposity were not observed when mice were housed under germ-free condition [216]. Along 
with these responses, the FFAR3-KO gnotobiotic mouse model exhibited both increased 
circulating levels of PYY and intestinal transit rate, which led to the assumption that SCFA-
mediated FFAR3 signaling is crucial for modulating host adiposity via reduced intestinal 
35 
 
 
 
lipid absorption and suppression of energy harvest capacity [216]. On the other hand, Kimura 
et al [217] has reported that FFAR2 activation suppressed insulin signaling in white adipose 
tissue, and thus altered glucose and lipid metabolism in FFAR2-KO mice fed a HFD. 
Additionally, FFAR2-KO mice, when fed a HFD, contained a higher proportion of 
Firmicutes and a lower level of proteobacteria and actinobacteria, a bacterial profile that has 
been associated with increased energy harvest capacity and obesity; however, treatment with 
antibiotics prevented the changes mentioned above and fecal SCFAs were similar to mice 
raised in a germ-free environment [217]. Taken together, the utilization of the FFAR-KO 
mouse models has shed a significant amount of light on role of FFAR signaling in SCFA-
mediated alterations in glucose and energy homeostasis. 
 
Intestinal gluconeogenesis  
In addition to FFAR signaling, the metabolic benefits of dietary fiber and RS could be 
attributed to intestinal gluconeogenesis upon stimulation by SCFAs. Interestingly, induction 
of intestinal gluconeogenesis has been associated with reduced food intake and hunger 
sensation, as well as suppression of hepatic gluconeogenesis and promotion of glycogen 
storage [218]. Furthermore, mice lacking intestinal gluconeogenic genes exhibited impaired 
glucose and insulin tolerance, which were accompanied with increased body weight [219]. It 
is also interesting to note that propionate and butyrate may regulate intestinal 
gluconeogenesis via different mechanisms. For instance, butyrate is able to up-regulate 
intestinal gluconeogenic gene expression in enterocytes via a cAMP-dependent pathway, 
independent of FFAR2 signaling. In contrast, propionate can up-regulate the gut-brain neural 
circuit via the activation of FFAR3 to induce intestinal gluconeogenesis [219]. The proposed 
mechanism of intestinal gluconeogenesis may explain, at least in part, the beneficial effects 
of SCFA on glucose and energy metabolism that could be beyond the energy harvest capacity 
of gut microbes.  
 
Resistant starch and kidney health 
 The prevalence of chronic kidney disease (CKD) is growing rapidly in the elderly 
population. According to the latest statistics published by the National Institute of Diabetes 
and Digestive and Kidney Disease, about 24.5% of the elderly U.S. population exhibit CKD 
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[220]. This alarming figure illustrates that the need to develop dietary interventions to 
prevent the incidence and progression of CKD is urgent. Because of the many links that 
investigators have made between the gut microbiome and obesity, the use of RS and other 
dietary fibers as substrates for microbial fermentation has been an area of increasing interest. 
While most studies involving the feeding of RS and other fermentable fibers have focused on 
obesity-related diabetes as discussed above, evidence has suggested that a number of dietary 
fibers promote kidney health [80, 221-224]. In patients with T2D, dietary fiber intake was 
strongly correlated with glycemic control and inversely correlated with the prevalence of 
metabolic syndrome [224]. Moreover, T2D patients who had a greater intake of dietary fiber 
had a lower risk for developing CKD [222, 223], which has been attributed to the anti-
inflammatory properties of certain types of fiber [224]. Xie and colleagues [222] also 
reported that the addition of 10 – 20 g /d of soluble fiber to the diet of hemodialysis patients 
for six weeks improved lipid profiles and reduced renal inflammation, which suggests that 
consumption of dietary fiber is critical for maintaining kidney health. Additionally, gum 
arabic and cellulose, when coupled with a low-protein diet, increased fecal nitrogen excretion 
[225, 226]. This suggests that consumption of these fibers restricted the growth of urease-
producing bacteria, which are known to damage epithelial tight junctions in CKD [227, 228]. 
Studies involving animal models of chronic kidney disease have also supported the beneficial 
effect of fermentable fibers in the attenuation of kidney inflammation and oxidative stress by 
reducing macrophage infiltration and apoptosis in the kidney [221, 223]. In addition, feeding 
of HAM, a source of RS2, delayed tubular damage and interstitial fibrosis in adenine-induced 
CKD mice, which could be related to SCFA-mediated normalization of gut epithelial tight 
junction protein expression [223]. Consistent with these findings, our laboratory has 
demonstrated that dietary RS delayed the progression of diabetic nephropathy in STZ-
induced T1D rats, though fasting blood glucose concentrations were not affected [80]. 
Intriguingly, expression of megalin and Dab2, which are critical for the uptake of the 25D-
DBP complex, was normalized by RS. In addition, urinary excretion of vitamin D 
metabolites was markedly reduced in RS-treated rats [80]. These findings suggest that RS is 
a dietary component that can potently influence vitamin D balance, which is disrupted in 
diabetes-related kidney disease. Furthermore, because the mechanisms responsible for the 
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beneficial effects of RS on kidney health are largely undefined, much more work is needed in 
this area. 
 
Conclusions 
Obesity-related diabetes is a growing epidemic that warrants the need for preventive 
therapies. As extensive literature reviews have consistently mentioned, the most effective 
preventative approach has been to maintain normal level of blood glucose in order to delay 
the progression of secondary complications that are a result of sustained hyperglycemia. 
Because maintaining kidney health is critical for vitamin D metabolism, we speculate that 
optimization of glycemic control could alleviate hyperglycemia-mediated kidney disease and 
restore vitamin D balance, which can ultimately prevent diabetic complications that are 
associated with vitamin D insufficiency, such as osteoporosis, cancer, and heart disease. To 
date, effective dietary interventions that target diabetic complications are still lacking. RS as 
a low glycemic fermentable fiber could be a potential candidate for the prevention of diabetes 
complications. The effect of RS on kidney health and vitamin D metabolism has been 
explored in our previous studies with T1D animal models. However, the effect of RS in T2D 
and T2D-induced kidney damage was still largely unknown until the studies described in 
future chapters of this dissertation were conducted. We based our hypotheses on the evidence 
that RS can have an impact on the development and progression of chronic kidney disease 
and metabolic control as presented in this literature review. Therefore, the goal of the studies 
we conducted was to evaluate the effect of RS on T2D-mediated kidney complications, 
including vitamin D homeostasis, and to explore the possible mechanisms that drive the 
renoprotective effect of RS in diabetes. This novel approach could lay down the foundation 
for the development of dietary strategies that can positively impact vitamin D balance and 
prevent diabetic complications that are also associated with aberrant vitamin D metabolism.  
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Abstract 
BACKGROUND: Type 2 diabetes (T2D) is the leading cause of nephropathy in the United 
States. Renal complications of T2D diabetes include proteinuria and suboptimal serum 25-
hydroxycholecalciferol (25D) concentrations.  25D is the major circulating form of vitamin 
D and renal reabsorption of the 25D-vitamin D-binding protein (DBP) complex via megalin-
mediated endocytosis is believed to determine whether 25D can be activated to 1,25-
dihydroxycholecalciferol (1,25D) or returned to circulation. We previously demonstrated that 
excessive urinary excretion of 25D-DBP and albuminuria occurred in type 1 (T1D) - and 
T2D rats. Moreover, feeding T1D rats high-amylose maize partially resistant to digestion 
(resistant starch; RS) prevented excretion of 25D-DBP, without significantly impacting 
hyperglycemia. 
METHODS: We utilized Zucker diabetic fatty rats (ZDF), a model of obesity-related T2D, 
to determine whether feeding RS could similarly prevent loss of vitamin D and maintain 
serum 25D concentrations. Lean control Zucker (n=8) rats were fed a standard semi-purified 
diet (AIN-93G) and ZDF rats were fed either the AIN-93G diet (n=8) or the AIN-93G diet in 
which cornstarch was replaced with RS (550 g/kg diet; 35% resistant to digestion, n=8) for 6 
wk.  
RESULTS: RS attenuated hyperglycemia by 41% and prevented urinary DBP excretion and 
albuminuria, which were elevated 3.0- and 3.6-fold, respectively, in control diet-fed ZDF 
rats. Additionally, urinary excretion of 25D and 1,25D was higher (89 And 97%, 
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respectively), whereas serum 25D concentrations were 31% lower in ZDF rats fed the control 
diet compared to RS-fed ZDF rats. Histopathological scoring of the kidney revealed that RS 
attenuated diabetes-mediated damage by 21% despite a ~50% decrease in megalin protein 
abundance. 
CONCLUSIONS: Taken together, these data provide evidence that suggests vitamin D 
balance can be maintained by dietary RS through nephroprotective actions in T2D, which are 
independent of vitamin D supplementation and renal expression of megalin. 
KEYWORDS: Resistant starch, high-amylose maize, diabetes, diabetic nephropathy, 
Zucker diabetic fatty rats, vitamin D, 25-hydroxycholecalciferol, megalin 
 
Introduction 
Type 2 diabetes (T2D) is an epidemic that has facilitated the need to develop feasible 
dietary strategies that can minimize the risk of developing secondary complications. Perhaps 
the most significant factor that must be considered when evaluating nutritional strategies for 
diabetics is kidney health, due in part to the role of the kidney in the reabsorption of nutrients 
[1]. It is estimated that out of all documented cases of renal failure in the United States, 
~44% are due to diabetes [2], which has implications in the development of nutrition-related 
complications. In the kidney, the major circulating form of vitamin D [25-
hydroxycholecalciferol (25D)] and the subsequent production of the active vitamin D 
hormone, 1,25-dihydroxycholecalciferol (1,25D) are dependent on receptor-mediated 
endocytosis of the 25D-vitamin D binding protein (DBP) complex by the proximal tubule [1, 
3-5]. Here, the endocytic proteins megalin and cubilin internalize the 25D-DBP complex 
from renal filtrate via endocytosis in concert with the intracellular adaptor protein disabled-2 
(Dab2) [3]. 25D is either hydroxylated by CYP27B1 to generate its active derivative, 1,25D, 
or returned to the circulation as 25D-DBP. Because the maintenance of circulating 25D and 
1,25D concentrations is dependent on kidney function, it is not surprising that compromised 
vitamin D status is a concern in diabetic patients [6-9], particularly those that experience 
symptoms of nephropathy [10-12]. Moreover, with a proclivity to exhibiting suboptimal 
vitamin D status, diabetics may be at an increased risk for developing complications that are 
consistent with vitamin D deficiency, such as bone disease, autoimmune disorders, and 
multiple forms of cancer, as has been comprehensively reviewed [13].  
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We recently reported that in both type 1 (T1D) and T2D animal models, urinary 
excretion of the 25D-DBP complex was markedly elevated [14, 15].   Specifically, we 
observed a marked increase in urinary 25D excretion. Furthermore, reduced expression of 
megalin and Dab2 was associated with a decline in serum 25D concentrations and loss of 
25D-DBP in the urine [14, 16, 17]. We also reported that these observations were prevented 
in dietary intervention studies with T1D rats, where feeding rats high-amylose maize, which 
is partially resistant to digestion, as a carbohydrate source, prevented the loss of renal 
megalin and Dab2 expression, as well as the urinary excretion of 25D and DBP [15].   
Resistant starch (RS) is a family of fermentable dietary fibers, some of which have 
been shown to improve the classic symptoms of obesity-related diabetes [18-20].  However, 
no published studies have reported a benefit of RS with respect to renal vitamin D 
metabolism and systemic vitamin D balance in obesity-related diabetes. In the present study, 
our objective was to determine whether feeding an AIN-93G diet in which the cornstarch was 
replaced with a carbohydrate source containing RS could protect against the perturbation of 
vitamin D metabolism in Zucker diabetic fatty (ZDF) rat, a well-characterized animal model 
of obesity-induced T2D. Specifically, we determined whether feeding ZDF rats high-amylose 
maize, which was chosen because it is partially resistant (~35%) to digestion [21], would 
maintain serum vitamin D status through the prevention of excessive urinary excretion of 
25D, 1,25D, and DBP.     
 
Materials and Methods 
Animals and Diets - All animal studies were approved by the Institutional Animal Care and 
Use Committee at Iowa State University and were performed according to Iowa State 
University Laboratory Animal Resources Guidelines. All diet ingredients, with the exception 
of high-amylose maize (Amylogel®, Cargill), were purchased from Harlan Teklad. Male 
ZDF and lean Zucker control rats were purchased at 8 wk of age (Charles River 
Laboratories) and housed individually in plastic cages in a room with a 12 h light-dark cycle 
and fed ad-libitum. Rats were randomly assigned to a diet (AIN-93G, Supplemental Table 1) 
containing either cornstarch (550 g/kg diet, C diet) or high-amylose maize (550 g/kg diet) 
that was ~35% resistant to digestion. Thus rats were divided into 3 groups (n=8): 1) lean 
control rats on a C diet (LC); 2) ZDF rats on a C diet (DC); 3) and ZDF rats on a RS diet 
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(DRS). All dietary starches were prepared as described previously [15]. The RS content (%) 
was verified in all diets over the 1 wk usage timeframe after it was prepared by in vitro 
digestion analysis (AOAC 991.43 Method) to confirm the stability of resistant starch [22]. 
All rats were provided free access to experimental diets and water for 6 wk. Prior to 
euthanization at the end of wk 6, rats were placed in metabolic cages for a 12 h fasting 
period. Subsequent urine samples were then collected and stored at -20°C until analysis. At 
the time of sacrifice, rats were anesthetized with a ketamine: xylazine cocktail (90:10 mg/kg 
body weight) via intraperitoneal injection. Whole blood was then collected via cardiac 
puncture and blood glucose concentrations were measured with a glucometer (Bayer 
Healthcare) after which tissues were removed and stored at -80°C prior to analysis.  
 
Assessment of urinary creatinine, total protein, albumin, and DBP - Urinary creatinine was 
measured using a commercial colorimetric kit (Cayman Chemical). Total urinary protein 
concentrations over 12 h were assessed using a bicinchoninic acid assay (Thermo Scientific 
Pierce). Urinary albumin and DBP were measured with commercial ELISA kits as described 
[15]. Urinary excretion of DBP and albumin were expressed as mg excreted/12 h.  
 
Assessment of urinary and serum 25D and 1,25D - Serum and urinary levels of 25D were 
measured via a commercial enzyme immunoassay kit (Immunodiagnostic Systems) as 
previously described [15].  Assessment of 1,25D in both serum and urine were measured 
with a commercially available ELISA kit (My BioSource, Inc.). The total urinary excretion 
of 25D and 1,25D was calculated and normalized to urinary creatinine as we have reported 
previously [15].    
 
RNA Isolation and Real-Time PCR - Total kidney RNA was isolated as previously 
described [15]. Total RNA was then quantified by UV detection and single-strand cDNA 
synthesis was carried out with a Verso cDNA Synthesis kit (Thermo Scientific). Real-time 
PCR reactions were performed in duplicate using iScript SYBR Green Detection reagents 
(Bio-Rad) at 200 ng/well for the detection of megalin, Dab2, CYP27B1, and CYP24A1 with 
an Applied Biosystems Plus® real-time PCR system (Life Technologies). The primers sets 
specific for megalin (forward primer: AACGGTCAGTGTATTCCGAGCGAA; reverse 
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primer: TTGGCAGTCGTCATCTCCATCACA), Dab2 (forward primer: 
AGGTTGAAGAAGCCAACAAAGCGG; reverse primer: 
AGTCCTGCTTTACGCCATTCGGTA), CYP27B1 (forward primer: 
GAGATCACAGGCGCTGTGAAC; reverse primer: 
TCCAACATCAACACTTCTTTGATCA), and CYP24A1 (forward primer: 
TGGATGAGCTGTGCGATGA; reverse primer: TGCTTTCAAAGGACCACTTGTTC), 
were normalized against 18S (forward primer: ACATCCAAGGAAGGCAGCAG; reverse 
primer: TTCGTCACTACCTCCCCGG).  Expression of each target gene was determined as 
mean fold change in gene expression relative to the non-diabetic animals (NDC).  
 
Histology and Immunohistochemistry. Kidneys were fixed in formalin, embedded in 
paraffin, sectioned at 5 µM, and stained with hematoxylin and eosin Y for histological 
assessment of kidney health. Histopathological scoring of kidneys was performed as 
described [23]. The lesions in the renal cortex that were evaluated included: tubular 
degeneration, interstitial fibrosis, dilated glomerular space, hydronephrosis, and dilated 
tubules in renal cortex. We performed Immunohistochemistry for the detection of Dab2 and 
megalin was done as described previously [14] and data were expressed as intensity per area.  
 
Statistical Analysis.  All data were analyzed via the Statistical Analysis System (SAS). 
Analysis of variance (ANOVA) with repeated measures was performed on the body weight 
changes and relative daily food intake. All other end-point analyses were evaluated 
statistically for differences between groups using one-way ANOVA followed by Tukey’s 
post hoc test. A non-parametric analysis was used when normality failed via Kruskal-Wallis 
one-way ANOVA by ranks followed by Tukey’s or Dunn’s multiple comparison test for 
unequal groups. Interactions between treatments and differences between means were 
considered significant at P ≤ 0.05.  
 
Results 
RS normalized growth pattern despite reducing food intake in ZDF rats.  By the beginning 
of the 3 wk treatment period, DRS rats gained considerably more weight than the LC and DC 
rats. By the of the 6 wk study, DRS rats gained 24 and 51% more weight than LC and DC 
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rats, respectively (Fig. 1A). Moreover, LC and DRS rats continued to gain weight throughout 
the treatment period, whereas the growth of the DC rats leveled off at wk 3 and rats did not 
gain any additional weight. However, these data do not reflect food intake by ZDF rats. 
Despite the DRS rats exhibiting the greatest growth rate out of any of the groups, they 
consumed 35% less diet by day 35 till the end of the treatment period, where they consumed 
40% less, when compared to DC rats (Fig. 1B).  
 
RS normalized blood glucose, urinary volume, creatinine excretion, and proteinuria in 
ZDF rats.  Compared to LC rats, fasting blood glucose concentrations were elevated 3-fold 
greater in the DC rats compared to a 1.4-fold increase in DRS rats and were 41% lower in the 
DRS rats compared to the DC rats (Table 1). Likewise, the total volume of urine collected 
during the 12 h fasting period was increased 1.9-fold in DC rats compared to both LC and 
DRS rats (Table 1). Urinary creatinine concentrations were 91 and 86% higher in LC and 
DRS rats, respectively, compared to DC rats; however there was no statistical difference 
between LC and DRS rats (Table 1).  Similarly, total urinary protein did not differ between 
LC and DRS rats, but was 4.2- and 1.6-fold higher in DC compared to LC and DRS rats, 
respectively (Table 1). Urinary albumin was 3.6-fold greater in DC than in DRS rats, and 
there were no differences in urinary albumin between LC and DRS rats (Table 1).  
 
Protection of the kidney by dietary RS rescued serum 25D concentrations and prevented 
urinary loss of 25D, 1,25D, and vitamin D-binding protein.  The renal histopathological 
score of the DC rats was highest among the treatments (48% higher than LC, Fig. 2A) and 
renal pathological scores of DRS rats did not differ from LC rats. Similarly, kidney weights 
in DC rats were greater than in LC and DRS rats (16% and 26%, respectively), and we did 
not detect a difference in kidney weight between the LC and DRS rats (Fig. 2B). Vitamin D 
status of the DC rats, as indicated by serum 25D concentrations, was 45% lower than in the 
LC rats and 31% lower than in DRS rats (Fig. 3A). Serum 1,25D did not differ between 
groups regardless of serum 25D status (Fig. 3B). Consistent with the decline in vitamin D 
status in DC rats, urinary excretion of DBP was markedly elevated in DC rats compared to 
LC rats, in which DBP was virtually undetectable, and was 75% greater in DC than in DRS 
rats (Fig. 3C). Moreover, urinary 25D concentrations were higher in DC rats compared to LC 
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and DRS rats (92 and 89% higher, respectively,) as were urinary 1,25D concentrations (94 
and 97% higher, respectively, Fig. 3D – 3E).  
 
mRNA expression of renal vitamin D transport and metabolism proteins did not change in 
ZDF rats regardless of diet. We did not detect any statistical differences in megalin, Dab2 
(Supplemental Fig. 1), CYP27B1, and CYP24A1 mRNA expression between any of the 
treatment groups (Supplemental Fig. 2). Unlike mRNA expression, immunohistochemical 
staining of the kidney sections revealed that megalin protein abundance in renal proximal 
tubules was ~50% lower in the DRS rats compared to the LC or DC rats (Fig. 4A). In 
contrast, expression of Dab2 protein in the renal proximal did not differ between DC and 
DRS rats, which was ~40- and 50% greater, respectively, than in LC rats (Fig. 4B).     
 
Discussion 
We have previously reported that vitamin D metabolism is disrupted in T1 and T2D 
and that dietary RS attenuated the urinary excretion of 25D in a model of T1D [14, 15]. Here, 
we demonstrate that the impact of dietary RS on maintaining vitamin D balance and the 
attenuation of symptoms were markedly more robust in T2D than what we found in our T1D 
studies.  Specifically, our data show that RS virtually prevented proteinuria and the urinary 
excretion of 25D and 1,25D, as well as maintained serum 25D concentrations. Furthermore, 
inclusion of dietary RS promoted the growth of DRS rats despite RS-fed rats consuming the 
lowest volume of diet based on body weight, indicating better overall health of DRS rats.  
It is interesting that body weight gain of the DRS rats was significantly higher than 
both LC and DC rats with no changes in food intake compared to LC rats. A typical symptom 
of uncontrolled diabetes with renal complications is glucosuria, which can lead to significant 
fluid and calorie loss [24]. We suspect a reason for our observation is that instead of 
excreting glucose in the urine, DRS rats likely were able to retain and store or metabolize it 
due to their better overall renal health. Consistent with this concept, RS attenuated the rise in 
fasting blood glucose concentrations in ZDF rats, which can explain, at least in part, the 
absence of osmotic diuresis due to hyperglycemia in RS-fed rats. However, these rats were 
still clearly diabetic as indicated by a glucose concentration that was over 2 × greater than in 
LC rats. Though DC rats fed the control diet consumed more overall diet than DRS rats and 
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thus more vitamin D, serum 25D levels in DRS rats were markedly higher compared to DC 
rats. These findings, combined with our histology data that demonstrated kidneys from DRS 
rats did not exhibit the same degree of pathology as DC rats, suggest that RS consumption 
did not prevent diabetes. Rather, it supports the possibility that dietary RS, due to the nature 
of its digestibility, attenuated a glycemic insult to the kidney of diabetic rats fed the 
cornstarch-based control diet. Thus kidney function was protected, which in turn promoted 
vitamin D balance in hyperglycemic ZDF rats.  
Surprisingly, we did not detect a decrease in mRNA expression of megalin and Dab2 
as we have consistently observed previously in diabetic rats [14, 15]. A possibility for this is 
that the macronutrient compositions are different between the AIN-93G diet we used for this 
work and the high-energy diabetogenic diet we used previously, which may have more 
strongly impacted renal health. Moreover, in our earlier studies, rats were fed a diabetogenic 
diet for 8 wk prior to sacrifice compared to a 6 wk feeding period of the AIN-93G diet for the 
present study. We also observed decreased megalin protein expression in the renal proximal 
tubules of DRS. Because our study demonstrated that RS protected kidney health in the ZDF 
rats, we suspect that the decreased expression of megalin in the proximal tubules of DRS rats 
may have been a protective action. 25D-DBP is one of many known megalin ligands, which 
also include pro-inflammatory cytokines, chemokines, and nephrotoxins [25, 26]. Our data 
also suggest that absorption of the 25D-DBP complex by the kidney can be achieved by 
different means. Thus, we have not ruled out the possibility that there is more than one 
mechanism by which the 25D-DBP complex can be internalized by renal proximal tubules. 
Furthermore, we are currently investigating the possibility that the activity and/or expression 
of megalin can be regulated at the translational or post-translational levels. Our earlier T2D 
work also involved dietary restriction of vitamin D to ZDF rats, which may help explain why 
we did not detect differences in the expression of CYP27B1 and CYP24A1 in the present 
study during which vitamin D intake was not restricted. Because both genes are potently 
regulated by 1,25D [27-29] a likely reason for no change in their expression is that serum 
1,25D concentrations were not different between any of the treatment groups, which was also 
observed in a recent clinical trial with T1D subjects [30].  
With the worldwide obesity-induced diabetes epidemic and the many questions that 
remain with respect to vitamin D requirements and vitamin D metabolism in diabetes, the 
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present study is timely as it is a highly translatable advancement in vitamin D research. 
Consistent with our animal studies, Thrailkill et al. [12] have observed elevated urinary 
excretion of 25D, 1,25D, and DBP in a clinical study with T1 diabetic subjects whom also 
exhibited compromised vitamin D status. Collectively, these are new insights into why 
suboptimal vitamin D status is common in diabetes and could prove to be valuable with 
respect to further interpretation of observational studies that reported compromised vitamin 
D status in both types of diabetes [31-34]. However, there is still a lack of controlled clinical 
trials that show vitamin D intervention can reduce the incidence and severity of diabetes. Yet 
in part due to the complexity of coordinating long-term trials with supplemental vitamin D, 
especially in diabetic patients, the knowledge gap with respect to the role of vitamin D in 
T2D outcomes may be difficult to overcome. Moreover, vitamin D trials in diabetic patients, 
which have mostly been utilized in the context of glucose metabolism, have not yielded 
promising results [35-38] and resistance to vitamin D supplementation has been reported in 
diabetic patients with suboptimal vitamin D status [39]. Elevated vitamin D excretion in both 
types of diabetes, as we have observed, could therefore be a significant limitation for such 
studies and thus a vitamin D supplement and/or UV exposure may not be effective for the 
maintenance of circulating vitamin D. Hence, alternative dietary strategies that can reduce 
the excretion of vitamin D may be more viable with respect to improving vitamin D status in 
diabetes. 
Here, we have demonstrated that independent of vitamin D supplementation, vitamin 
D balance can be protected from the effects of obesity-induced diabetes through the inclusion 
of RS in the diet. Because the ZDF rat is an extreme model of T2D compared to what is 
typical of a human with T2D, it is reasonable to hypothesize that the beneficial effects of RS 
on vitamin D balance could be produced in a clinical setting by a diet containing less RS than 
we utilized for this study. In support of this concept, we have recently found that reducing the 
RS content in the diet by half of what was utilized in the present study normalized growth of 
T1D rats (Koh and Rowling, unpublished observations).  Additionally, our future work will 
focus on whether other types of dietary fiber could provide similar benefit with respect to 
vitamin D balance and the prevention of vitamin D-related secondary complications.   
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 LC DC DRS P value 
12h Urinary volume, mL 5.3 ± 0.1
b 
15.3 ± 2.4
a 
5.4 ± 0.6
b 
P <  0.001 
Fasting blood glucose, mg/dL 149 ± 16.4
c 
594 ± 53.9
a 
351 ± 46.7
b 
P < 0.0001 
Urinary total protein, mg/12 h 35.2 ± 7.7
b 
183 ± 32.7
a 
70.0 ± 14.5
a 
P <  0.001 
Urinary albumin, mg/12 h 0.1 ± 0.0
b 
45.7 ± 16.9
a 
3.1 ± 1.8
b 
P <  0.01 
Urinary creatinine, mg/dL 169 ± 47.5
a
 15.3 ± 4.1
b 
107 ± 13.1
ab 
P <  0.01 
1
Values are means ± SEM (n = 7-8).  Mean values within a row without a common letter 
differ, P < 0.05. DC, Zucker diabetic fatty rat fed a standard semi-purified AIN-93G control 
diet containing 55% cornstarch; DRS: Zucker diabetic fatty rat fed a resistant starch diet in 
which the cornstarch was replaced with an equivalent amount of high-amylose maize; LC, 
Zucker diabetic fatty rat fed a standard semi-purified AIN-93G control diet.   
Table 1. Biochemical measurements LCs, DCs, and DRSs.
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Fig. 1. Dietary resistant starch prevented growth stunting of ZDF rats. A) Cumulative 
body weight gain of LCs, DCs, and DRSs. Rats were fed experimental diets for 6 wk. B) 
Daily food intake (in g) of LCs, DCs, and DRSs consumed per kilogram body weight per 
day. Data are expressed as mean ± SEM (n = 8). At each time point, values with different 
letters differ, P < 0.05. DC, Zucker diabetic fatty rat fed a standard semi-purified AIN-
93G control diet containing 55% cornstarch; DRS: Zucker diabetic fatty rat fed a resistant 
starch diet in which the cornstarch was replaced with an equivalent amount of high-
amylose maize; LC, Zucker diabetic fatty rat fed a standard semi-purified AIN-93G 
control diet; ZDF, Zucker diabetic fatty.   
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Fig. 2. Dietary resistant starch improved the renal histopathology scoring in 
ZDF rats. A) Renal histopathological scores of LCs, DCs, and DRSs. B) Kidney 
weight of LCs, DCs, and DRSs. Data are expressed as means ± SEM (n = 4). Bars 
with different letters differ, P < 0.05. DC, Zucker diabetic fatty rat fed a standard 
semi-purified AIN-93G control diet containing 55% cornstarch; DRS: Zucker 
diabetic fatty rat fed a resistant starch diet in which the cornstarch was replaced 
with an equivalent amount of high-amylose maize; LC, Zucker diabetic fatty rat 
fed a standard semi-purified AIN-93G control diet;  ZDF, Zucker diabetic fatty. 
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Fig. 3. Dietary resistant starch maintained circulating 25D concentrations and 
prevented urinary excretion of 25D, 1,25D, and DBP in ZDF rats. A) Serum 25D 
concentrations in in LCs, DCs, and DRSs. B) Serum 1,25D concentrations in LCs, DCs, and 
DRSs. C) Urinary DBP excretion by LCs, DCs, and DRSs. D) Urinary 25D excretion by 
LCs, DCs, and DRSs. E) Urinary 1,25D excretion by LCs, DCs, and DRSs. Data are 
expressed as means ± SEM (n = 5 – 8). Bars with different letters differ, P < 0.05. DBP, 
vitamin D-binding protein; DC, Zucker diabetic fatty rat fed a standard semi-purified AIN-
93G control diet containing 55% cornstarch; DRS: Zucker diabetic fatty rat fed a resistant 
starch diet in which the cornstarch was replaced with an equivalent amount of high-amylose 
maize; LC, Zucker diabetic fatty rat fed a standard semi-purified AIN-93G control diet; 
ZDF, Zucker diabetic fatty; 1,25D, 1,25-dihydroxycholecalciferol; 25D, 25-
hydroxycholecalciferol.    
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Fig. 4. Renal megalin expression was reduced and DAB2 expression was 
enhanced by dietary resistant starch in the kidneys of ZDF rats. A) Renal 
expression of megalin in LCs, DCs, and DRSs. B) Renal expression of Dab2 in LCs, 
DCs, and DRSs. Data are expressed as means ± SEM (n = 4). Bars with different 
letters differ, P < 0.05. DAB2, disabled-2; DC, Zucker diabetic fatty rat fed a standard 
semi-purified AIN-93G control diet containing 55% cornstarch; DRS: Zucker diabetic 
fatty rat fed a resistant starch diet in which the cornstarch was replaced with an 
equivalent amount of high-amylose maize; LC, Zucker diabetic fatty rat fed a standard 
semi-purified AIN-93G control diet; ZDF, Zucker diabetic fatty. 
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CHAPTER 4: CONSUMPTION OF DIETARY RESISTANT STARCH FOLLOWING 
THE ONSET OF DIABETES DOES NOT PREVENT HYPERGLYCEMIA AND 
COMPROMISED KIDNEY FUNCTION 
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Abstract 
BACKGROUND: The morbidity and mortality rates of diabetes are contingent upon the 
development of secondary complications. Our laboratory has previously demonstrated that 
feeding of dietary resistant starch (RS) prior to the onset of diabetes delayed the progression 
of diabetic nephropathy and maintained vitamin D balance in streptozotocin (STZ)-induced 
T1D diabetic rats. In the present study, we conducted a dose response study with RS and 
assessed kidney function and vitamin D homeostasis following the onset of diabetes in STZ-
treated rats.      
METHODS: Male Sprague-Dawley (SD) rats were administered STZ (n = 8/group) and fed 
either a semi-purified diet (AIN-93G) containing 550 g/kg of corn starch (CS), 550 g/kg of 
high-amylose maize (HRS), a carbohydrate source rich in type 2 resistant starch , 275 g/kg of 
resistant starch + 275 g/kg of corn starch (MRS), or 138 g/kg of resistant starch + 412 g/kg of 
corn starch (LRS). Vehicle-treated rats fed an AIN-93G diet containing 550 g/kg of 
cornstarch served as a non-diabetic control group (NDC). All rats were maintained on the 
experimental diet for 4 wk.   
RESULTS: T1D rats fed the MRS and HRS diet gained 52% and 73% more weight, 
respectively, than CS-fed rats. No differences in weight gain were detected between CS and 
LRS rats. In contrast to our previous RS intervention study, in which rats were fed RS prior 
to injection with STZ, RS did not modulate renal health, as indicated by urinary creatinine 
and albumin concentrations in T1D rats. Fasting blood glucose concentrations, hemoglobin 
A1c%, and fasting insulin concentrations were also not affected by RS. Despite excessive 
excretion of urinary 25-hydroxycholecalciferol (25D), serum 25D concentrations were 
significantly higher in RS-fed T1D rats compared to NDC rats. Overall, circulating IL-6 
concentrations were 9 – 31% higher in RS-fed T1D rats, compared to CS rats regardless of 
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improved vitamin D status, and were strongly correlated with hyperglycemia (r = 0.472; P = 
0.02). No changes in serum TNF-α concentrations were detected.   
CONCLUSIONS: Dietary RS normalized growth patterns in T1D rats following the onset of 
diabetes in a dose-dependent manner despite having no effect on blood glucose and serum 
25D concentrations.  
KEYWORDS: 25-hydroxycholecalciferol; diabetic nephropathy; high-amylose maize; 
hyperglycemia; interleukin-6; Streptozotocin; type 1 diabetes; resistant starch; vitamin D 
 
Introduction 
Diabetes is an epidemic that affects approximately 23 million Americans [1]. If left 
uncontrolled, diabetes typically leads to severe macrovascular and microvascular 
complications such as atherosclerosis, retinopathy, and neuropathy. It is the progression of 
such secondary complications that determines the morbidity and mortality associated with 
diabetes. A complication associated with diabetes that has significant implications with 
respect to nutritional status is nephropathy, which constitutes 44% of documented kidney 
failure cases in the United States according to the National Institute of Diabetes and 
Digestive and Kidney Disease [2]. In addition to its role in the filtration of waste and toxins, 
the kidney is critical for nutrient reabsorption. Thus, it is not surprising that compromised 
kidney function can lead to vitamin D deficiency because vitamin D, as 25-
hydroxycholecalciferol (25D), is reabsorbed or activated to 1,25-dihydroxycholecalciferol 
(1,25D) in the kidney. Uptake of 25D by the renal proximal tubular cells is dependent on the 
internalization of the 25D-vitamin D binding protein (DBP) complex by the endocytic 
receptor proteins, megalin and cubilin, as well as the adaptor protein disabled-2 (Dab2) [3, 
4]. We have previously demonstrated that excessive urinary excretion of 25D and DBP due 
to reduced kidney function led to compromised vitamin D status in type 2 diabetic (T2D) rats 
[5]. Therefore, it is not surprising that low vitamin D status has been consistently linked with 
diabetes [6-8]. Furthermore, several studies have demonstrated that like diabetes, suboptimal 
vitamin D levels are linked to an increased prevalence of bone disease, autoimmune 
disorders, and various types of cancer [9-11]. Because of the diverse biological actions of 
vitamin D, maintaining kidney health in diabetes for maintenance of vitamin D balance could 
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be critical to the prevention of secondary complications that are associated with low vitamin 
D status. 
We have recently reported that the inclusion of high-amylose maize (HAM), which 
contains ~35% of type 2 resistant starch (RS2), as a substitute for cornstarch in the AIN-93G 
diet, promoted renal health and vitamin D balance in animal models of type 1 diabetes (T1D) 
[12] and type 2 diabetes (T2D) [13]. While T2D is characterized by insulin resistance, T1D is 
usually mediated by an autoimmune response and is characterized by dysfunctional or 
destroyed pancreatic beta cells. There are multiple reports that suggest vitamin D has an 
important immunomodulatory role [14-16]. In addition, low vitamin D status was associated 
with increased incidence of T1D [15, 16] and microalbuminuria in T1D patients [17, 18].  
Although the causal relationship between vitamin D and T1D remains largely unknown, our 
laboratory observed that rats fed RS prior to STZ injection exhibited normal vitamin D 
balance and attenuated nephropathy [12]. Specifically, we found that RS-feeding reduced 
urinary excretion of 25D and DBP and normalized renal expression of megalin and Dab2 
[12]. These findings suggest that the inclusion of RS into the diet could be an effective means 
to prevent aberrant vitamin D metabolism.   
RS is a class of fermentable carbohydrates that has been shown to improve insulin 
sensitivity and reduce abdominal adiposity in obesity-related diabetes [19-21]. RS2 in 
particular is abundant in raw starchy vegetables and fruits such as potato and unripe banana.  
The source of RS2 in our previous work was high-amylose maize (HAM), which contains an 
amylose-extender mutant that allows the maize to contain a higher concentration of amylose, 
and thus it is more resistant to enzymatic hydrolysis [22]. RS2 from HAM is highly 
fermentable by the gut microbiota [23, 24] and has been shown to reduce adiposity and 
postprandial glycemic response in obese animals [20, 21, 25]. We have previously reported 
that feeding rats HAM prior to the induction of diabetes by STZ prevented nephropathy and 
vitamin D imbalance. The objectives of the current study, therefore, were to: 1) determine 
whether feeding HAM to rats following the induction of T1D could promote renal health and 
vitamin D balance and 2) whether these effects could be produced by feeding T1D rats lower 
doses of RS2 than we have utilized previously.  
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Materials and Methods 
Animals and Diets. All procedures and protocols performed were approved by the 
Institutional Animal Care and Use Committee at Iowa State University and in compliance 
with Iowa State University Laboratory Animal Resources Guidelines. Male Sprague-Dawley 
(SD) rats were purchased at 4 wk of age from Harlan and were housed individually in plastic 
cages with free access to food and water. Diet ingredients (AIN-93G) were purchased from 
Harlan Teklad, whereas high-amylose maize (Amylogel®) was obtained from Cargill. To 
induce T1D, streptozotocin (STZ, 60 mg/kg) in 10 mM citrate buffer (pH 4.5) was injected 
into the intraperitoneal cavity (i.p.) of SD rats at 5 wk of age. Control rats (NDC) (n = 8) 
were injected with an equal volume of citrate buffer. NDC rats were then fed the AIN-93G 
diet, which contains cornstarch at a level of 550 g/kg diet. All STZ-treated SD rats were 
randomly assigned to 4 groups after STZ injection (n = 8/group) and fed AIN-93G diet, 
which contained either 550 g/kg of corn starch (CS), 550 g/kg of HAM (HRS), 275 g/kg of 
HAM + 275 g/kg of corn starch (MRS), or 138 g/kg of HAM + 412 g/kg of corn starch 
(LRS) for 4 weeks. All diets were prepared as previously described and RS content was 
analyzed as we have previously reported [12, 13]. Our analysis revealed that the HAM used 
for this study was 35% resistant to digestion. Thus, the final RS content in the LRS, MRS, 
and HRS diets was 5%, 10%, and 20%, respectively. Prior to the termination of study, all rats 
were fasted overnight for 12 h in individual metabolic cages and urine was collected then 
frozen at -20°C until analysis. Prior to the collection of blood and tissues, rats were 
anesthetized with a ketamine: xylazine cocktail (90: 10 mg/kg BW) that was injected i.p. 
Whole blood was then collected via cardiac puncture and an aliquot was kept in EDTA-
coated vacutainer at 4°C for glycated hemoglobin analysis. The remaining blood was stored 
in a serum tube and allowed to clot at room temperature for 15 min prior to centrifugation at 
2000 × g for 15 min. Serum was transferred into a microcentrifuge tube and kept at -20°C 
until analysis. Liver and kidneys were removed, weighed, and stored at -80°C until analysis.  
 
Assessment of blood glucose, hemoglobin A1c, and serum insulin. Blood glucose was 
measured using a glucometer (Bayer Healthcare) at the time of sacrifice. Hemoglobin A1c% 
(HbA1c%) was measured in whole blood samples within 48 h of sacrifice with a commercial 
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kit (Stanbio). Serum insulin concentrations were measured with a commercial ELISA kit 
(Millipore).   
 
Assessment of urinary creatinine, urinary albumin, and vitamin D status. Urinary 
creatinine, albumin, DBP, and 25D as well as serum 25D were assessed using commercial 
available kits as we have reported previously [5, 12, 13]. Total urinary excretion of albumin, 
DBP, and 25D over 12 h was normalized to urinary creatinine as we have previously reported 
[5, 12, 13].  
 
Assessment of serum pro-inflammatory markers. Serum TNF-α (R&D systems) and serum 
IL-6 (Thermo Scientific) were analyzed via commercial ELISA kits. Data were expressed as 
fold changes relative to NDC rats.   
 
Statistical Analysis. Data were analyzed with Statistical Analysis System (SAS 9.4) using 
one-way ANOVA followed by a Fisher Least Square Difference (LSD) post-hoc test. 
Outliers were detected by Mixed Model Influential Diagnostics and removed if internal 
studentized residuals were outside the interval of [-2.5, 2.5]. Correlation analysis was 
assessed between fasting blood glucose concentrations, serum IL-6 concentrations, and 
serum TNF-α concentration by a Pearson Product-Moment Correlation test. Significance of 
all tests was set at P ≤ 0.05.  
 
Results 
Dietary RS partially corrected the growth pattern in STZ-treated rats in a dose-dependent 
manner. When combined, all T1D rats gained significantly less weight than NDC rats 
throughout the 4 wk treatment period, (Fig. 1). CS rats gained 65% less weight than the NDC 
rats, but no differences in weight gain were detected between the CS and LRS. However, 
MRS- and HRS-fed T1D rats gained approximately 52% and 73% more weight, respectively, 
compared to CS rats (Fig. 1). Although RS prevented normalized growth patterns in the T1D 
rats in a dose-dependent manner, fasting blood glucose concentrations, hemoglobin A1c%, 
and insulin levels were not affected by RS diets (Table 1). Kidney weight in CS rats was 1.7-
fold greater than in NDC rats, but did not differ from LRS and MRS rats. Kidney weight in 
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HRS rats was 20% lower than in CS rats, though it was still 36% greater than in NDC rats 
(Table 1). With respect to liver weight, we did not detect differences in T1D rats, regardless 
of RS dose (Table 1). In addition, both urinary creatinine (Supplemental Fig. 1) and albumin 
(Supplemental Fig. 2) in T1D rats were ~3- to 5.5-fold lower, and ~4- to 6-fold greater 
compared to NDC, respectively, but did not differ among the RS-fed T1D rats.  
 
Serum 25D concentrations were elevated in T1D rats despite excessive urinary excretion of 
25D and DBP. Overall, urinary excretion of DBP was 21- to 32-fold greater in T1D rats 
compared to NDC rats. LRS, MRS, and HRS diets reduced excretion of DBP by 15%, 36%, 
32% in T1D rats, respectively, when compared to CS rats (Fig. 2A). All T1D rats excreted 
3.5- to 6-fold higher amount of 25D in the urine compared to control rats, but no differences 
were detected between the T1D rats regardless of dietary RS content (Fig 2B). Urinary 
excretion of 25D and DBP had no impact on vitamin D status in T1D rats. Serum 25D 
concentrations in T1D rats were between 33 - 45% higher than in NDC rats regardless of 
dietary RS content (Fig 2C). In addition, average daily intake of vitamin D was ~2-fold 
higher in T1D rats compared to NDC rats (Fig 2D).  
 
Circulating IL-6 concentrations were enhanced by dietary RS in T1D rats and correlated 
with hyperglycemia. Because a pro-inflammatory state is highly associated with the 
development of microvascular complications in diabetes, we assessed the effect of RS on the 
secretion of pro-inflammatory cytokines, TNF-α and IL-6 in T1D animals. Specifically, we 
tested whether the presence of these cytokines correlated with vitamin D status and 
progression of diabetic nephropathy in T1D rats. As a whole, serum IL-6 concentrations were 
higher in RS-fed T1D rats than in NDC and CS rats (Fig. 3A). Specifically, LRS-, MRS-, and 
HRS-fed T1D rats exhibited 31%, 9%, and 31% higher circulating IL-6 concentrations 
compared to CS rats (Fig. 3A). On the contrary, we did not detect any differences in 
circulating TNF-α among all groups (Fig. 3B). Additionally, circulating IL-6, but not TNF-α, 
correlated with hyperglycemia (r = 0.472; P = 0.02) (Fig. 4). No correlation was identified 
between IL-6, vitamin D status, and renal function.  
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Discussion 
In the present study, we demonstrated that inclusion of dietary RS normalized the 
growth pattern of T1D rats. Because the total weight gain in both MRS- and HRS-fed T1D 
rats did not differ from the CS rats, we estimate that the minimal effective dose that can 
impact the growth of T1D rats is 10% dietary RS. Body weight fluctuation is a common 
symptom of T1D. Because dietary RS attenuated the catabolic nature of uncontrolled T1D in 
our study, which indicates that though a number of parameters did not differ between RS-
treated and CS-fed T1D rats, these results suggest that RS-fed T1D rats exhibited better 
overall health. Yet, the growth pattern improvement in RS-fed rats was independent of 
hyperglycemia and vitamin D status, and  was not associated with inflammation status as 
serum IL-6 concentrations in these rats were still significantly higher than in CS rats. 
However, since our study was limited to the measurement of two pro-inflammatory 
cytokines, TNF-α and IL-6, we recognize that a full inflammatory panel may reveal that 
other factors play a larger role with respect to inflammation status in our animal model.  
Previously, we reported that feeding rats HAM prior to induction of T1D normalized 
growth patterns and attenuated urinary excretion of 25D and serum proteins [12]. Based on 
these observations, we hypothesized that the renoprotective effect of dietary RS may have 
partially contributed to the overall weight maintenance because the RS-fed T1D rats were 
less diabetic and therefore likely retained calories from glucose and protein. Interestingly, our 
results show that though growth stunting was attenuated by RS in a dose-dependent manner, 
growth rate appeared to be independent of kidney function since no differences were detected 
in urinary creatinine or urinary albumin between groups (Supplemental Fig. 1 and Fig. 2). 
One possibility with respect to the normalized growth pattern in T1D rats by RS is that RS 
influenced the secretion of  glucagon-like protein 1 (GLP-1) and peptide YY (PYY), gut 
hormones that are known to mediate postprandial satiety. Dietary RS has been reported to 
enhance GLP-1 and PYY secretion in vivo [26]. GLP-1 has also been shown to improve beta 
cell proliferation and insulin secretion. Hence, GLP-1 agonists have been widely used as a 
co-treatment for T1D and T2D to delay the progression of diabetes and attenuate diabetic 
symptoms [27-29]. Therefore, it is possible that RS enhanced insulin secretion via a GLP-1-
mediated pathway, which in turn could have promoted energy retention and growth in T1D 
rats.  
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Here, we reported that kidney function did not appear to be protected by RS when RS 
feeding was introduced following the induction of T1D. This is in contrast with our previous 
study where we found that RS, when fed to T1D rats prior to induction of T1D, attenuated 
urinary loss of vitamin D and maintained renal integrity [12]. Because RS2 is fermentable, 
we speculate that feeding RS before the induction of diabetes may have altered the microbial 
composition of the gut. We hypothesize this based on reports that SCFA production or other 
products of fermentation can provide protection against nephropathy [30-32]. In fact, it has 
been shown that modulation of the gut microflora through the supplementation of probiotics 
and fermentable fibers reduced the incidence of T1D [33, 34] and chronic kidney disease [35, 
36], suggesting that the composition of the microbiome can, at least in part,  modulate the 
risk of T1D development and complications that occur during its progression.  
Vitamin D status, as indicated by serum 25D concentrations, was greater in all 
diabetic groups compared to control rats, even though T1D rats excreted higher amounts of 
25D and DBP. Because we observed hyperphagia in T1D rats, a likely explanation for the 
increase in serum 25D concentrations is that a higher intake of vitamin D compensated for 
the urinary excretion of 25D. As vitamin D status has been inversely associated with the 
incidence of both T1 and T2D [15, 16], we expected to observe at least moderate 
amelioration of diabetic symptoms in rats with higher serum concentrations of 25D. Our 
current data showed that vitamin D status in T1D rats had no impact on circulating pro-
inflammatory cytokines, fasting blood glucose, or HbA1c%. Similar to the current study, 
Shih et al. [37] reported that correction of vitamin D deficiency had no effect on 
inflammation and other diabetic symptoms in adolescents with T1D. It is possible that the 
onset of nephropathy or other diabetic complications promoted oxidative stress and an 
inflammatory state in the T1D rats used in our studies, which may have confounded the 
protective effect of vitamin D. In support of this concept, we showed that RS did not improve 
glucose metabolism in T1D rats while serum IL-6 concentrations, a pro-inflammatory 
cytokine, were strongly correlated with hyperglycemia. Consistent with our findings, Jaacks 
et al [38] reported that dietary fiber intake among youth who were diagnosed with T1D was 
not associated with systemic inflammation. In contrast, C-reactive protein and fibrinogen 
concentrations, the positive acute-phase proteins secreted in response to inflammation,  were 
inversely correlated with fiber consumption in non-diabetic adolescents [39], indicating that 
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the mechanism of by which dietary fiber such as RS impacts inflammation could be 
dependent on glycemic status.  
 Taken together, we speculate that the time at which dietary RS is introduced is critical 
with respect to providing nephroprotection in T1D. This may also partially explain our 
observation that kidney health, and thus vitamin D balance, was protected in T1D rats when 
RS was given prior to the onset of diabetes [12]. In line with our observations, others have 
reported that the protective actions of 1,25D in T1D were most effective when treatment was 
given at weaning (prior to insulitis onset) rather than when insulitis was already present [40-
42]. Hence, our future work will focus on the development of preventative strategies with RS 
that will delay or prevent the onset of diabetic nephropathy and secondary complications 
associated with suboptimal levels of vitamin D.  
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Table 1. Glucose homeostasis and tissue weight in NDC, CS, LRS, MRS, and HRS
 
following 4 wks of treatment
1 
 
1
Data are expressed as mean ± SEM (n = 6 – 8). Mean values across the row with different 
letters are differ, P ≤ 0.05. All rats were fed experimental diets for 4 weeks as indicated in 
Materials and Methods. NDC, non-diabetic rats fed AIN-93G diet; CS, T1D rats fed AIN-
93G diet; LRS, T1D rats fed AIN-93G diet containing 5% RS; MRS, T1D rats fed AIN-93G 
diet containing 10% RS; HRS, T1D rats fed AIN-93G diet containing 20% RS. 
 
 
 
  
  NDC CS LRS MRS HRS 
Fasting blood 
glucose, mg/dL 
108 ± 8.7
a
 598 ± 134
b
 636 ± 95
b
 472 ± 91
b
 535 ± 103
b
 
Hemoglobin 
A1c, % 
  
3.84 ± 0.67
a
 6.08 ± 0.67
ab
 6.51 ± 1.20
b
 5.62 ± 1.13
ab
 5.87 ± 0.63
ab
 
Insulin, ng/mL 1.65 ± 0.33
b
 0.83 ± 0.07
a
 0.72 ± 0.02
a
 0.94 ± 0.08
a
 0.97 ± 0.06
a
 
 
Liver, g/kg of 
body weight  
  
2.77 ± 0.04
c
 4.84 ± 0.42
ab
 5.33 ± 0.13
a
 4.27 ± 0.35
b
 4.21 ± 0.27
b
 
Kidney, g/kg of 
body weight 
0.36 ± 0.01
d
 0.61 ± 0.05
ab
 0.64 ± 0.03
a
 0.51 ± 0.04
bc
 0.49 ± 0.03
c
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Fig. 1. Dietary resistant starch (RS) attenuated body weight loss at a dose-dependent 
manner in T1D rats. STZ was injected i.p. at Day 0 and all rats were fed experimental diets 
for 4 wks starting on Day 1 as indicated in Materials and Methods. NDC, non-diabetic rats 
fed a AIN-93G diet; CS, T1D rats fed AIN-93G diet; LRS, T1D rats fed AIN-93G diet 
containing 5% RS; MRS, T1D rats fed AIN-93G diet containing 10% RS; HRS, T1D rats fed 
AIN-93G diet containing 20% RS. Baseline body weight gain is indicated as pre-
streptozotocin (STZ) injection. Data are means ± SEM (n = 8/group). Groups with different 
letters differ (P < 0.05).   
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Fig 2.  RS attenuated urinary DBP, but not 25D excretions in T1D rats. A) Urinary DBP, 
B) urinary 25D, C) serum 25D, D) mean daily intake of vitamin D in NDC, CS, LRS, MRS, 
and HRS rats. All rats were fed experimental diets for 4 weeks as indicated in Materials and 
Methods. NDC, non-diabetic rats fed AIN-93G diet; CS, T1D rats fed AIN-93G diet; LRS, 
T1D rats fed AIN-93G diet containing 5% RS; MRS, T1D rats fed AIN-93G diet containing 
10% RS; HRS, T1D rats fed AIN-93G diet containing 20% RS. Data are means ± SEM (n = 
6-8/group). Groups with different letters differ (P < 0.05).  
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Fig 3.  RS elevated circulating IL-6, but not TNF-α in T1D rats. A) Serum IL-6 and B) 
serum TNF-α concentration in NDC, CS, LRS, MRS, and HRS rats. All rats were fed 
experimental diets for 4 weeks as indicated in Materials and Methods. NDC, non-diabetic 
rats fed AIN-93G diet; CS, T1D rats fed AIN-93G diet; LRS, T1D rats fed AIN-93G diet 
containing 5% RS; MRS, T1D rats fed AIN-93G diet containing 10% RS; HRS, T1D rats fed 
AIN-93G diet containing 20% RS. Data are means ± SEM (n = 5/group). Groups with 
different letters differ (P < 0.05).   
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Fig 4. Circulating IL-6 concentrations were strongly correlated to fasting blood glucose 
concentrations. Each symbol represents data for an individual rat (N = 25).  
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CHAPTER 5: DIFFERENTIAL EFFECTS OF HIGH- AND LOW-DOSE DIETARY 
RESISTANT STARCH ON VITAMIN D HOMEOSTASIS AND RENAL FUNCTION 
IN ZUCKER DIABETIC FATTY RATS 
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Emily Wisecup, Kevin L. Schalinske, and Matthew J. Rowling 
 
Abstract 
BACKGROUND: Diabetic nephropathy increases the risk for vitamin D deficiency due in 
part to the role of kidney in maintaining circulating 25-hydroxycholecalciferol (25D) 
concentrations. We previously reported that high-amylose maize (HAM), which contains 
starch that is partially resistant to digestion (RS) protected kidney health and maintained 
vitamin D status in Zucker diabetic fatty rats (ZDF), an experimental model of type 2 
diabetes. Here, our objectives were to determine if a lower dose of RS could similarly 
promote kidney health and vitamin D balance, as well as to further elucidate the mechanism 
behind our earlier observations in RS-fed ZDF rats.  
METHODS: Lean Zucker rats (n=5) were fed control diet (LC); ZDF rats (n = 5/group) 
were fed either control diet (DC), diet containing 10% RS (MRS), or diet containing 20% RS 
(HRS) for 6 wks.  
RESULTS: Neither the HRS nor MRS diets attenuated blood glucose levels and hemoglobin 
A1c % in ZDF rats. However, serum insulin concentrations were 1.5-fold greater and 
HOMA-β% was 2-fold greater in HRS-fed rats compared to DC rats. The increase in insulin 
secretion was not observed in MRS-fed rats. Additionally, the HRS, but not MRS diet, 
improved vitamin D status and attenuated urinary loss of vitamin D metabolites in ZDF rats. 
Serum triglycerides were 50% lower in HRS-fed rats compared to DC rats, despite a 2-fold 
increase in hepatic triglycerides. Circulating adiponectin concentrations were 77% higher in 
HRS-fed rats, but no difference was detected in MRS-fed rats, compared to DC rats. 
Furthermore, adiponectin concentrations were strongly correlated with serum 25D 
concentrations (r = 0.815, P < 0.001), urinary protein (r = -0.583, P = 0.02) and urinary 
creatinine (r = 0.818, P < 0.001), respectively. Serum angiotensin II was 44% lower, and a 
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14-fold increase in renal nephrin expression was observed in HRS-fed rats compared to DC 
rats, but no changes were detected in MRS-fed rats.  
CONCLUSIONS: Here, we provide the first evidence that the maintenance of vitamin D 
balance and renoprotection we observed in the RS-fed ZDF rats was strongly correlated with 
serum adiponectin levels and reduced circulating angiotensin II concentrations, which can be 
achieved with 20% RS, but not at lower intake of RS.  
KEYWORDS: 25-hydroxycholecalciferol; adiponectin; angiotensin II; diabetic 
nephropathy; high-amylose maize; renin-angiotensin system; resistant starch; type 2 
diabetes; vitamin D; Zucker diabetic fatty rat 
 
Introduction 
Type 2 diabetes (T2D) is strongly associated with the development of kidney disease 
and T2D patients account for ~44% of the documented renal failure cases in the United 
States. Diabetic nephropathy has significant implications with respect to nutrient deficiencies 
due to the central role of the kidney in maintaining circulating levels of numerous nutrients. 
We previously reported that compromised kidney function in Zucker Diabetic fatty rats 
(ZDF), an animal model of T2D, lead to aberrant vitamin D metabolism, mainly due to 
excessive urinary excretion of vitamin D metabolites [1]. Reabsorption as well as activation 
of 25-hydroxycholecalciferol (25D) to 1,25-dihydroxycholecalciferol (1,25D) by 1-α 
hydroxylase is highly dependent on the internalization of the circulating 25D-vitamin D 
binding protein (DBP) complex in the renal proximal tubule [2, 3]. Hence, it is speculated 
that diabetic-induced kidney disease may be the underlying factor of vitamin D deficiency in 
T2D. Moreover, suboptimal vitamin D status is highly associated with the development of 
secondary complications [4], which may further increase morbidity and mortality in T2D 
patients. Therefore, comprehensive strategies to optimize nutritional status and attenuate 
complications associated with diabetic kidney disease in T2D are highly warranted.   
One of the common therapeutic interventions for delaying the progression of diabetic 
nephropathy involves the utilization of angiotensin-converting enzyme inhibitors (ACEi) [5-
9], which suggests that the renin-angiotensin system (RAS) is highly involved in the 
promotion of diabetic complications. The RAS is a multifaceted hormonal system that is 
essential for regulating arterial pressure, as well as fluid and electrolyte balance. Angiotensin 
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II, an effector of RAS, has been shown to enhance inflammation and promote vascular 
dysfunction, insulin resistance, and oxidative stress during the progression of diabetes [10-
14]. It is also interesting to note that treatment with ACEi and angiotensin II receptor 
(AGTR) inhibitors increased plasma adiponectin levels in patients with metabolic syndrome 
[15, 16]. Adiponectin is an adipokine secreted by adipose tissue that is inversely related to 
obesity [17]. In addition to the regulation of insulin sensitivity [18, 19], adiponectin has been 
shown to exert renoprotective effects in animal models of kidney disease [20-22]. The 
interaction between adiponectin and the RAS was further established when adiponectin 
treatment attenuated angiotensin II-mediated oxidative stress in cultured proximal tubular 
cells [23, 24] and delayed the progression of diabetic nephropathy in db/db mice without 
affecting blood glucose levels [24]. These observations indicate that adiponectin is a 
suppressor of the RAS. Yet, dietary interventions to target the RAS are still lacking.  
We previously demonstrated that high-amylose maize (HAM), a rich source of 
resistant starch (RS), promoted vitamin D balance in type 1 (T1) [25] and type 2 (T2) 
diabetic rats [26] by attenuating symptoms of diabetic nephropathy. RS is a class of 
fermentable fibers with low glycemic indices. Thus, inclusion of RS into the diets of 
diabetics is a promising strategy. Moreover, RS has been shown to ameliorate the symptoms 
of obesity-related diabetes [27-29] and retard the progression of chronic kidney disease [30]. 
Intriguingly, our results indicate that though dietary RS2, provided by feeding high-amylose 
maize (HAM), protected kidney health of T2D rats, it did not prevent hyperglycemia [25, 
26], which lead us to suspect that the renoprotective effect of RS in T2D may occur via 
suppression of RAS activity. The health benefits of low glycemic carbohydrates with respect 
to the kidney health and vitamin D metabolism in diabetes have been supported by work in 
our laboratory that demonstrated that RS attenuated nephropathy and prevented excessive 
urinary excretion of vitamin D metabolites [25, 26]. Thus, the objective of the present study 
was to determine whether the prevention of symptoms of nephropathy and maintenance of 
vitamin D balance in T2D that we have previously observed in RS-feeding studies could be 
achieved at a lower intake of dietary RS. Moreover, we determined whether RS could impact 
adiponectin and angiotensin II concentrations as well as downstream targets of angiotensin II 
in the kidney that have been linked to diabetic nephropathy. 
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Materials and Methods 
Animals and Diets. All procedures and protocols were approved by the Institutional Animal 
Care and Use Committee at Iowa State University and were conducted under the Iowa State 
University Laboratory Animal Resources Guidelines. All AIN-93G diet ingredients were 
purchased from Harland Teklad, whereas HAM (Amylogel®) was purchased from Cargill. 8 
wk old male ZDF and lean Zucker rats were procured from Charles River Laboratories and 
housed individually in plastic cages in a room with a 12-h light-dark cycle with free access to 
food and water. Lean Zucker rats (n = 5) fed the AIN-93G diet containing 550 g/kg of corn 
starch served as the lean control group (LC). ZDF rats were randomly assigned to the three 
following diets (n = 5 rats/group): 1) AIN-93G diet containing 550g/kg of cornstarch (DC), 
2) AIN-93G diet containing 275g/kg of cornstarch and 275g/kg of HAM (MRS), or 3) AIN-
93G diet where cornstarch was replaced by 550g/kg of HAM (HRS) for 6 wk. Experimental 
diet preparation and subsequent RS content analyses were conducted as described previously 
[25, 26]. Our analysis revealed that the HAM used in this study was ~35% resistant to 
digestion, and thus yielded a final concentrations of 20% RS in the HRS diet and 10% RS in 
the LRS diet, respectively. All rats were fasted for 12 h in individual metabolic cage prior to 
sacrifice. Urine and fecal samples were collected during the fasting period and stored at -
20°C. Rats were anesthetized with a ketamine: xylazine cocktail (90:10 mg/kg of body 
weight) via an intraperitoneal injection at the time of sacrifice and whole blood was collected 
via cardiac puncture. A portion of whole blood was collected in EDTA-coated vacutainer and 
stored at 4°C. The remaining blood was collected into a serum tube and subjected to 
centrifugation at 2000 × g for 15 min. Serum was transferred to a microcentrifuge tube and 
kept at -20°C until analysis. Liver, visceral fat, and whole kidneys were removed, weighed, 
and stored at -80°C until analysis or fixed in 10% formalin for histopathological 
examination.  
 
Assessment of blood glucose, hemoglobin A1c, and serum insulin. Blood glucose 
concentrations were measured with a glucometer (Bayer Healthcare) immediately after blood 
collection. Whole blood samples were processed within 48 h from the time of sacrifice for 
hemoglobin A1c (HbA1c) analysis via a commercial kit (Stanbio). Serum insulin was 
assessed with an ELISA kit (Millipore). Pancreatic beta cell function (%) was calculated 
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based on the Homeostasis Model Assessment for beta-cell function (HOMA-β):   
 
 
Assessment of urinary creatinine, total protein, and albumin. Urinary creatinine was 
analyzed with a commercial colorimetric kit (Cayman Chemical). Urinary protein was 
measured using the bicinchoninic acid assay (Thermo Scientific Pierce) and urinary albumin 
was assessed with an ELISA kit (Innovative Research) as described previously [1, 26]. Total 
urinary excretion of protein, and albumin over 12 h were calculated and expressed relative to 
urinary creatinine.   
 
Assessment of urinary and serum 25D and 1,25D. Analysis of urinary and serum 25D were 
conducted using a commercial enzyme immunoassay kit (Immunodiagnostic Systems). 
Serum and urinary concentration of 1,25D were assessed via a commercial ELISA kit (My 
BioSource). Urinary excretion of 25D and 1,25D were normalized to urinary creatinine as 
described previously [1, 26].   
 
Assessment of hepatic and serum triglycerides. Total hepatic lipids were extracted using the 
Folch method [31]. Both hepatic and serum triglyceride levels were then determined using a 
commercially available colorimetric triglyceride assay kit (BioAssay Systems). Hepatic 
triglyceride concentrations were calculated and expressed as mg triglyceride per g of liver.    
 
Assessment of circulating adiponectin and angiotensin II. Serum angiotensin II (Sigma-
aldrich) and serum adiponectin (R&D system) were analyzed with commercially available 
ELISA kits. 
 
Real-time PCR. Kidney RNA was extracted and quantified by UV detection as described 
previously [1, 26]. Total RNA was reverse transcribed into cDNA via a Verso cDNA 
Synthesis Kit (Thermo Scientific). Real-time PCR reactions were conducted in duplicate at 
200 ng/well of cDNA with iScript SYBR Green Detection Reagents (Bio-Rad) for the 
detection of angiotensin II receptor type 1a (AGTR1a), angiotensin II receptor type 2 
(AGTR2), angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2), 
HOMA-β % = [360 × Insulin (mU/L)] / Glucose (mg/dL) – 63 
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and nephrin with an Applied Biosystems Plus® real-time PCR system (Life Technologies). 
Expression of each gene was normalized against 18s or GAPDH. The mRNA expression for 
each gene was expressed as mean fold change relative to lean control animals. The primer 
sequences are presented in Supplemental Table 1. 
 
Renal Histology. To assess renal histopathological changes in animals, whole kidneys were 
fixed in formalin, embedded in paraffin, sectioned at 3 µM, and subjected to hematoxylin and 
eosin Y staining. Scoring of kidneys was performed as described previously [26]. 
 
Statistical Analysis. Data were analyzed with the Statistical Analysis System (SAS 9.4). Data 
were analyzed using one-way ANOVA followed by Fisher Least Square Difference (LSD) 
post-hoc test. If normality failed, non-parametric analysis was used via Kruskal-Wallis one-
way ANOVA by ranks. Correlation of serum adiponectin concentrations with serum 25D, 
urinary creatinine, and urinary protein concentrations were determined by Pearson Product-
Moment Correlation. Significance of all tests was set at P ≤ 0.05.  
 
Results 
HRS normalized the growth pattern and lowered serum triglycerides of ZDF rats 
independent of serum glucose concentrations and the accumulation of hepatic 
triglycerides. Throughout the 6 wk study, LC and HRS rats exhibited continual weight gain, 
whereas weight gain of DC and MRS rats plateaued by wk 5. At the end of the 6 wk study, 
HRS rats gained 48% and 47% more weight than DC and MRS rats, respectively (Table 1). 
Nonetheless, the difference in weight gain was not affected by food intake (data not shown). 
In addition to weight gain, fasting blood glucose concentrations in HRS rats were 20% lower 
and serum insulin concentrations were 1.5-fold higher compared to DC rats, though 
hemoglobin A1c levels (HbA1c %) were 21% higher (Table 1). To further evaluate beta cell 
function, HOMA-β% was calculated. HRS rats exhibited the greatest HOMA-β values (2.3- 
and 4.1-fold greater than in DC and MRS rats, respectively), which did not differ from LC 
rats (Table 1). No significant changes in blood glucose levels, HbA1c %, serum insulin 
levels, and HOMA-β were observed between DC and MRS rats (Table 1). Interestingly, 
serum triglycerides (TG) were 50% lower in HRS-fed ZDF compared to DCs despite a 2-fold 
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increase in hepatic TGs. In contrast, although the MRS diet attenuated serum TG as we 
observed in HRS rats, hepatic TG did not differ between MRS and DC rats (Table 1).  
 
HRS improved markers of kidney function and vitamin D status in ZDF rats despite an 
increase in renal histopathological scoring. Total urine volume was 5-fold higher in DC 
than in LC rats, and no differences were detected between HRS and LC rats (Table 2). Urine 
volume of MRS rats was 36% lower compared to DC rats, yet it was not significantly 
different from DC or LC rats. Urinary creatinine concentrations from HRS rats were 90% 
and 76% greater than from DC and MRS rats, respectively, but were still significantly lower 
(55% lower) compared to LC rats (Table 2). Urinary albumin and protein concentrations 
from HRS rats were markedly lower compared to DC rats (99% and 94% lower, 
respectively) and these values were not statistically different from LC rats. In contrast, 
urinary albumin and protein concentrations from MRS rats did not differ from LC or DC rats. 
Urinary loss of both 25D (Fig. 1A) and 1,25D (Fig. 1B) was greater (40-fold and 24-fold 
higher, respectively) in DC rats than in LC rats. The HRS diet prevented excessive excretion 
of vitamin D metabolites in ZDF rats compared to DC rats as indicated by a 94% and 92% 
reduction in urinary 25D and 1,25D, respectively, and did not differ from LC rats (Figs. 1A 
and 1B). Unlike the rats fed the HRS diet, urinary 25D loss in MRS rats did not differ from 
DC or LC rats. Similarly, we did not detect any difference in urinary 1,25D concentrations 
between MRS and DC rats (Figs. 1A and 1B). Serum 25D concentrations in LC rats were the 
highest, where they were 36% and 58% greater than in DC and MRS rats, respectively. 
Serum 25D levels in HRS rats, however, did not differ from LC or DC rats. While no 
differences were detected in serum 1,25D concentrations between the LC, DC, and HRS rats, 
they were 4.6-fold lower in MRS compared to LC rats (Fig.1D). Markers of kidney function 
and vitamin D status were normalized in MRS and HRS rats; however, renal 
histopathological scores did not differ between ZDF rats regardless of dietary treatment 
(Supplement Fig. 1).   
 
Circulating adiponectin concentrations were elevated in HRS rats independent of adiposity 
and correlated with serum 25D concentrations and urinary markers of kidney health. LC 
rats exhibited the lowest visceral fat content among all the groups (Fig. 2A) and serum 
106 
 
 
 
adiponectin concentrations in LC rats were 2.5-fold greater than in DC rats (Fig. 2B). Despite 
no difference in visceral fat among all ZDF rats, circulating adiponectin concentrations were 
77% higher in HRS compared to DC rats, but we did not detect statistical differences 
between MRS and DC rats (Fig. 2B). Among all animals included in this study, serum 
adiponectin concentrations correlated with serum 25D levels (r = 0.815, P < 0.001) (Fig. 3A) 
and urinary creatinine excretion (r = 0.818, P < 0.001) (Fig. 3B), and inversely correlated 
with urinary protein excretion (r = -0.583, P = 0.02) (Fig. 3C).     
 
HRS-fed ZDF rats exhibited reduced serum angiotensin II concentrations and greater 
renal nephrin gene expression. Serum angiotensin II concentrations in HRS-fed ZDF rats 
were 44% lower compared DC rats (Fig 4A). Yet, no differences were observed between LC, 
DC, and MRS rats. To determine the impact of RS on renal RAS activity, we analyzed renal 
expression of AGTR1a, an angiotensin II receptor that mediates vascular smooth muscle 
responses once activated by angiotensin II. MRS and HRS diets attenuated the expression of 
renal AGTR1a in ZDF rats by 4.5-fold and 3.2-fold, respectively, compared to DC rats (Fig 
4B). No changes were detected in all groups with respect to other renal RAS markers, which 
included the expression of ACE, as well as ACE2 and AGTR2 that are known to counteract 
the effect of angiotensin II (data not shown). Due to its role in regulating glomerular 
permeability, we further examined the expression of nephrin. Renal nephrin mRNA 
expression was 14-fold greater in HRS than in DC rats and we detected no differences in 
nephrin expression between LC, DC, and MRS rats (Fig. 4C).  
 
Discussion 
Dietary interventions targeting T2D have largely focused on the impact of a low 
glycemic index diet on diabetes incidence and progression, which originally led us to design 
a diet that included HAM containing ~35% RS, as a strategy to prevent diabetes-associated 
complications. We reported that RS promoted vitamin D metabolism balance and kidney 
health in T1 [25] and T2 [26] diabetic rats, though both of these models remained 
hyperglycemic throughout the experimental period. Here, we found that feeding ZDF rats a 
diet containing 55% of HAM (HRS) promoted a linear growth pattern, maintained vitamin D 
balance, and normalized markers of kidney function in HRS-fed ZDF. Yet, we did not 
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observe the same level of a response, with respect to proteinuria and vitamin D balance in 
MRS-fed rats. Thus, based on our results it seems likely that the minimal effective dose of 
RS to produce these results is closer to 20% of the diet.  
One possible mechanism by which the reduction of RS dosage by half (MRS) did not 
provide a benefit equal to the HRS diet in ZDF rats in the current study could be explained 
by lower production of colonic fermentation products in MRS rats. RS is a fermentable fiber 
that can serve as a substrate for gut microbiota production of short chain fatty acids (SCFA), 
such as butyrate. Indeed, intravenous administration of butyrate delayed the progression of 
kidney failure in rodent models of nephropathy [32, 33]. Hence, it is plausible that the 
amount of SCFA produced by MRS-fed ZDF rats was insufficient to provide renal 
protection. Similar to our observations, Robertson et al. [34] reported that consumption of 60 
g of RS/d enhanced postprandial insulin sensitivity in healthy subjects but not in those who 
consumed 40 g of RS/d, and improvements in glucose tolerance were associated with higher 
plasma SCFA concentrations. Surprisingly, histopathological changes were not observed in 
the RS-fed rats in this study as we have observed previously [26]. We suspect that this 
observation can be partially explained by a difference in diabetes onset between this group of 
rats and the rats used in our previous study. Despite the absence of visually detectable 
differences in the kidney, a number of parameters that are used to assess kidney function 
were normalized by RS. Since we have consistently observed an improvement in various 
markers of kidney function and vitamin D balance in HRS-fed ZDF rats, we postulate that 
normalized kidney function by RS-feeding maybe attributed by a number of external factors 
such as systemic regulation of arterial pressure by angiotensin II, oxidative stress, and 
fibrosis, all of which we are currently investigating. 
T2D is typically characterized by hyperinsulinemia due to increased insulin secretion 
by beta cells to compensate for impaired clearance of blood glucose due to a lack of insulin-
mediated GLUT-4 activation. If left untreated, prolonged hyperglycemia in T2D often leads 
to beta cell apoptosis and an insulin-dependent condition [35]. In the present study, we 
observed that serum insulin concentrations among all ZDF rats were elevated by 67% - 87% 
compared to lean Zucker rats.  However, insulin levels in HRS rats were the greatest among 
all treatment groups. Because our data showed that HOMA-β% was 2-fold greater and 
insulin secretion was 1.5-fold greater in HRS rats compared to DC rats, it is possible that 
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HRS delayed beta cell apoptosis. This could also possibly explain the attenuation of 
hyperglycemia by the HRS but not the MRS diet. Additionally, we have not ruled out the 
possibility that reduction of fasting blood glucose in HRS-fed ZDF rats was a result of 
increased circulating adiponectin concentrations. In support of this concept, dietary RS 
improved insulin sensitivity in aged mice, which was partially attributed to increased 
adiponectin secretion from visceral fat [29]. It is also interesting to note that HRS rats 
exhibited the greatest accumulation of hepatic TGs, though serum TG concentrations were 
50% lower in HRS rats compared to DC rats. Others have shown that overexpression of 
SREBP-1c, a known transcription factor in fatty acid metabolism that is regulated by insulin, 
induced hepatic lipid synthesis and down-regulated lipid oxidation enzymes [36, 37]. 
Although the underlying mechanisms are not fully understood, it was postulated that hepatic 
TG accumulation was due to the up-regulation of SREBP-1c by insulin and the inhibition of 
hepatic VLDL export, which in theory would result in reduced serum TG concentrations, and 
be consistent with our observations. 
Our data indicate that neither the MRS nor the HRS diet attenuated hyperglycemia, 
which suggests that the protection of kidney in ZDF was mediated by other means, such as 
RAS activation. We postulate this because therapeutic approaches with ACEi have yielded 
promising results with respect to the attenuation of diabetic nephropathy [5-8], which would 
be consistent with our data that showed that circulating angiotensin II concentrations were 
suppressed by the HRS diet. Since renal expression of AGTR1a were also lowered by the 
HRS diet and we did not observe any changes in the expression of other RAS components, it 
is possible that RS may have protected kidney health in ZDF rats via the suppression of 
AGTR1a-induced signaling upon binding to angiotensin II. Interestingly, circulating 
angiotensin II and renal expression of AGTR1a were greater in LC rats compared to HRS-fed 
ZDF rats, indicating that the phenotypic response resulting from systemic or local 
suppression of angiotensin II could be dependent upon glycemic status. Moreover, since our 
data demonstrated that adiponectin concentrations strongly correlated with vitamin D status 
and inversely correlated with urinary albumin and protein, and that renal AGTR1a expression 
was reduced in HRS-fed ZDF rats, it is plausible that these parameters could have been 
modulated by adiponectin, a known suppressor of angiotensin II activity. As opposed to the 
HRS diet, the MRS diet modestly affected kidney function and vitamin D homeostasis. 
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Furthermore, circulating adiponectin and angiotensin II concentrations were not affected in 
MRS-fed ZDF rats, though renal AGTR1a expression was suppressed. Several studies have 
demonstrated that RAS inhibition was consistent with elevated plasma adiponectin 
concentrations in patients with metabolic syndrome [15, 16, 38]. Thus, our findings support 
the idea that RS modulates renal angiotensin II-induced signaling through an adiponectin-
dependent mechanism. Besides, adiponectin-knockout mice exhibited increased albuminuria 
and podocyte injury whereas treatment with adiponectin blunted the symptoms of renal 
injury and attenuated angiotensin II-induced oxidative stress in an animal model of chronic 
kidney disease [20, 21, 23, 24].  One potential mechanism by which adiponectin could have 
promoted renal handling of the 25D-DBP complex in ZDF rats may be the induction of 
nephrin expression. Nephrin is a slit diaphragm-associated protein that is vital in maintaining 
renal filtration barrier. Hence, suppression of nephrin expression could be an early event in 
the progression of diabetic nephropathy [39]. Moreover, RAS antagonists have been shown 
to preserve nephrin expression and reduce albuminuria independent of the presence of 
glomerular lesions in diabetic animals [39, 40].  
In the current study, nephrin expression was markedly elevated in HRS rats, which 
was accompanied by a reduction in serum angiotensin II, renal mRNA expression of 
AGTR1a, albuminuria, and proteinuria. Although the causal relationship remains to be 
elucidated, we speculate that the HRS diet could have, at least in part, prevented proteinuria 
and excessive loss of 25D in ZDF rats by maintaining the expression of nephrin, which may 
have been driven by adiponectin-mediated suppression of angiotensin II. Although the 
underlying mechanism is still unclear, our future work will focus on the modulation of the 
RAS system and perhaps an intervention involving a combination of dietary RS and ACEi, 
the latter which is routinely used for the amelioration of diabetic nephropathy symptoms, 
with the goal of providing protection against diabetic complications that are associated with 
suboptimal vitamin D status.       
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   Table 1. Biochemical measurements of LC, DC, MRS, and HRS
1
  
 
 LC DC MRS HRS 
Total body weight 
gain, g 
113 ± 4.8
b
 115 ± 15
b
 116 ± 21
b
 167 ± 3.1
a
 
Fasting blood 
glucose, mg/dL 
 
153.8 ± 8.4
b
 570 ± 70
a
 585 ± 130
a
 407 ± 43
ab
 
HbA1c, % 
 
6.76 ± 0.55
b
 7.45 ± 0.72
ab
 9.05 ± 0.90
a
 9.55 ± 0.61
a
 
Serum insulin, ng/mL 
 
0.82 ± 0.05
b
 2.83 ± 0.73
ab
 2.51 ± 1.06
ab
 4.41 ± 1.01
a
 
HOMA-β, % 
 
88.1 ± 12.1
ab
 57.6 ± 19.5
b
 31.8 ± 10.0
b
 132 ± 36.5
a
 
Serum triglycerides, 
mg/dL  
 
63.6 ± 15.4
c
 800 ± 17
a
 386 ± 88
b
 401 ± 51
b
 
Hepatic triglycerides, 
mg/g of liver 
 
2.22 ± 0.08
c
 6.98 ± 0.50
b
 7.71 ± 1.46
b
 13.4 ± 0.86
a
 
1
Data are expressed as mean ± SEM (n = 3 – 5). Mean values across the row with different   
letters are differ, P ≤ 0.05. LC, lean Zucker rats fed the control diet; DC, ZDF rats fed control 
diet; MRS, ZDF rats fed diet containing 10% resistant starch; HRS, ZDF rats fed diet 
containing 20% resistant starch. HOMA-β, Homeostasis Model Assessment for beta-cell 
function; ZDF, Zucker diabetic fatty.  
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Table 2. Assessment of renal function in LC, DC, MRS, and HRS following 6 wks of 
treatment
1
   
 
 LC DC MRS HRS 
12-h urinary volume, mL 
 
 
4.90 ± 0.68
b
 14.5 ± 3.10
a
 9.25 ± 1.92
ab
 5.80 ± 0.72
b
 
Urinary creatinine, mg/dL 
 
140 ± 17
a
 6.66 ± 1.81
c
 15.0 ± 4.2
c
 63.6 ± 5.9
b
 
Urinary albumin,  
µg/mg of creatinine 
 
0.0 ± 0.0b 3.89 ± 1.74a 1.56 ± 0.29ab 0.03 ± 0.01b 
Urinary protein,  
µg/mg of creatinine 
 
0.70 ± 0.01
b
 20.5 ± 5.0
a
 8.61 ± 3.54
ab
 1.22 ± 0.41
b
 
1
Data are expressed as mean ± SEM (n = 4 – 5). Mean values across the row with different 
letters are differ, P ≤ 0.05. LC, lean Zucker rats fed the control diet; DC, ZDF rats fed control 
diet; MRS, ZDF rats fed diet containing 10% resistant starch; HRS, ZDF rats fed diet 
containing 20% resistant starch; ZDF, Zucker diabetic fatty.  
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Fig. 1. HRS attenuated excessive urinary excretion of 25-hydroxycholecalciferol (25D) 
and 1,25-dihydroxycholecalciferol (1,25D) and maintained circulating 25D in  Zucker 
diabetic fatty rats (ZDF). A) Serum 25D concentrations, B) serum 1,25D concentrations, C) 
urinary excretion of 25D, and D) urinary excretion of 1,25D.  Data are means ± SEM (n = 4) 
where bars with different letters differ, P ≤ 0.05. LC, lean Zucker rats fed the control diet; 
DC, ZDF rats fed control diet; MRS, ZDF rats fed diet containing 10% resistant starch; HRS, 
ZDF rats fed diet containing 20% resistant starch; ZDF, Zucker diabetic fatty. 
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Fig. 2. HRS enhanced serum adiponectin concentrations in Zucker diabetic fatty rats 
(ZDF) despite no significant change in visceral fat content. A) Visceral fat content and B) 
serum adiponectin concentrations. Data are means ± SEM (n = 4 - 5) where bars with 
different letters differ, P ≤ 0.05. LC, lean Zucker rats fed the control diet; DC, ZDF rats fed 
control diet; MRS, ZDF rats fed diet containing 10% resistant starch; HRS, ZDF rats fed diet 
containing 20% resistant starch; ZDF, Zucker diabetic fatty. 
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Fig. 3. Serum adiponectin strongly correlated with improved kidney function and 
serum 25D concentrations.  Serum adiponectin concentrations correlated with A) serum 
25D concentrations, B) urinary creatinine, and C) urinary protein. Each symbol represents 
data for an individual rat, where each group is represented by a discrete symbol (n = 
4/group). LC, lean Zucker rats fed the control diet; DC, ZDF rats fed control diet; MRS, ZDF 
rats fed diet containing 10% resistant starch; HRS, ZDF rats fed diet containing 20% resistant 
starch; ZDF, Zucker diabetic fatty; 25D, 25-hydroxycholecalciferol. 
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Fig. 4. HRS reduced serum angiotensin II concentrations and increased renal mRNA 
expression of nephrin in Zucker diabetic fatty rats (ZDF). A) Circulating angiotensin II 
concentrations, B) renal angiotensin II receptor type 1a (AGTR1a) mRNA expression, and C) 
renal nephrin mRNA expression in LC, DC, MRS, and HRS.  LC, lean Zucker rats fed the 
control diet; DC, ZDF rats fed control diet; MRS, ZDF rats fed diet containing 10% resistant 
starch; HRS, ZDF rats fed diet containing 20% resistant starch; ZDF, Zucker diabetic fatty. 
Data are means ± SEM (n = 3 - 5) where bars with different letters differ, P ≤ 0.05. 
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CHAPTER 6: GENERAL CONCLUSIONS 
 
Overall Summary and Conclusions 
The studies presented in this dissertation have demonstrated that dietary resistant 
starch (RS) has a renoprotective role. In these studies, feeding RS promoted kidney health 
and vitamin D balance in ZDF rats, a well-established animal model of type 2 diabetes. 
Specifically, high-amylose maize (HAM), as a source of RS, prevented proteinuria and 
albuminuria, which together, prevented urinary vitamin D excretion through its protective 
actions in the kidney of ZDF rats. Results obtained from study two and study three suggest 
that the minimal effective dose of RS, based on the attenuation of diabetic nephropathy 
symptoms, would be between 275g/kg to 550 g/kg of HAM in the total diet, translated into 
10 – 20% of RS, assuming that HAM is ~35% resistant to digestion. Although dietary RS 
appeared to improve kidney health, ZDF rats fed RS were still clearly diabetic as indicated 
by HbA1c% and fasting blood glucose levels. Hence, we believe that the delayed progression 
of kidney damage in ZDF rats by RS is mediated by local RAS signaling upon the 
stimulation of adiponectin, a mechanism that promotes the expression of nephrin, a protein 
central to maintaining the integrity of the renal filtration barrier (Fig. 1). Yet, we cannot 
exclude the possibility that RS may have a direct effect on renal RAS and nephrin 
expression. Interestingly, fasting insulin concentrations were significantly higher in HRS-, 
but not MRS-treated ZDF rats, compared to diabetic control rats. While the underlying 
mechanism is still uncertain, these reported observations could be a potential indication of 
improved pancreatic function and insulin sensitivity, which may also partially explain the 
elevated hepatic TG accumulation and reduced serum TG in ZDF rats.    
In study 2, where we utilized STZ-induced T1D diabetic rats, we illustrated that the 
renoprotective effect of dietary RS is likely dependent on the stage of diabetes when RS 
feeding is introduced. Our laboratory has previously reported that feeding a HAM-containing 
diet prior to STZ injection attenuated the symptoms of diabetic nephropathy in rats that later 
developed diabetes following STZ treatment [1]. However, our study showed that treatment 
with dietary RS following the onset of diabetes did not exert similar effect on kidney 
function, though dietary RS promoted growth of T1D rats in a dose-dependent manner. 
Because RS is a fermentable fiber, it is reasonable to argue that diabetes onset altered the gut 
121 
 
 
 
microbiota composition in T1D rats that is reasonable to argue that diabetes onset altered the 
gut microbiota composition in T1D rats that could diminish the beneficial effect of RS in 
diabetic rats. In addition, the marked hyperglycemia following STZ injection may have 
greatly enhanced oxidative stress and inflammation status that potentiated the progression of 
diabetes in our T1D model. This is supported by our data that indicated that hyperglycemia 
Fig. 1. Proposed renoprotective mechanism of dietary resistant starch in type 2 diabetes 
mediated by renal renin-angiotensin system. Direct effect of resistant starch on renal 
angiotensin II receptor type 1a and nephrin remained to be determined (dotted line). 
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was strongly associated with serum IL-6 concentration, a pro-inflammatory cytokine, in STZ 
rats. We anticipate that optimal glycemic control could potentially augment the effect of RS 
on the kidney, and thus inclusion of RS in the diet should be introduced during the early 
onset of diabetes as a preventive intervention to delay diabetic complications.   
 
Strengths and Limitations 
Our novel approach in developing a dietary intervention via the utilization of dietary 
RS to delay the progression of diabetic nephropathy in ZDF rat model was the key strength 
of this study. More importantly, the ability of dietary RS to ameliorate other diabetic 
symptoms, such as vitamin D status, insulin sensitivity, hyperglycemia, and serum 
triglycerides, support its application in diabetes management. 
One major limitation in the study was a low sample size that decreased the power to 
detect a treatment effect. Based on the current data on serum 25D concentrations (study 1), 
we would expect a sample size greater than 6 animals per group is needed to reach a power 
of 0.9.  However, the sample size estimation via power analysis is limited to detecting a 
difference in serum 25D levels and does not account for other variables. Due to high inter-
individual variation, sample size of each group should be carefully determined by using 
multiple variables. Another limitation involves the use of ZDF rat, a leptin-deficient model of 
type 2 diabetes. Because ZDF is an extreme model of T2D and leptin deficiency is rare in 
humans, we are uncertain whether the differences in T2D pathophysiology in humans are 
comparable to what we have reported in ZDF rats. Furthermore, the role of leptin signaling 
towards the renoprotection of RS in ZDF has been excluded in the present studies. Thus, 
results should be carefully addressed when it comes to translating the beneficial effect of RS. 
Multiple animal models, such as the use of high-fat diet induced or spontaneous diabetic 
animal models should be taken into consideration.    
Another concern of the studies described in this dissertation was the RS dosage. On 
average, it has been reported that Americans only consume and average of 5 g of RS per day 
[2]. Our studies demonstrated that 550 g/kg of HAM exerted a protective effect in ZDF with 
respect to maintaining vitamin D balance, which is equivalent to the consumption of ~55 g of 
RS per day in a human diet of 2000 kcal/day. Our studies showed that renal health was not 
protected to the same degree in both the T1D or T2D animal models when RS dose was 
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reduced by half (10% RS or 275 g/kg of HAM). Thus, a combination approach with 
pharmaceutical drugs, such as ACEi or other dietary interventions may be a more effective 
and viable intervention. Nonetheless, the studies presented in my dissertation are perhaps the 
only evidence that shows that dietary RS promoted kidney health in diabetes, which in turn, 
normalized vitamin D metabolism in well-established diabetes models, possibly via an 
adiponectin-mediated angiotensin II suppression pathway.   
 
Future research 
The health benefits of dietary RS has been widely described and confirmed by many 
researchers, including our most recent studies targeting the renoprotective action of dietary 
RS and its impact on vitamin D metabolism. However, there are still questions that remain to 
be answered: 1) What is the mechanism underlies the elevated adiponectin concentration in 
HRS-fed ZDF? 2) What would be the potential mechanism by which RS enhanced insulin 
concentrations in ZDF rats and how would that associate with hepatic accumulation and lipid 
metabolism? 3) What is the potential role of vitamin D in RAS? 4) What is the potential role 
of short chain fatty acid production by the gut microflora in diabetic nephropathy?  
Moreover, to further define the mechanism underlying the renoprotective effect of 
RS, in vitro studies that target specific tissues could be employed to examine the changes of 
biomarkers relevant to local RAS signaling or other possible pathways. As our current results 
suggest, the mechanism by which RS promotes kidney health in our diabetic models is 
unknown and rather complex. Future studies should consider the use of complimentary or a 
combination approach with RS, such as ACEi, other fiber types, and functional ingredients 
that have been proven effective against diabetes to optimize the protective effect of RS in 
diabetes mellitus and its associated complications.  
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APPENDIX A: LIST OF ABBREVIATIONS 
 
1,25D   1,25-dihdroxycholecalciferol  
25D   25-hydroxycholecalciferol  
ACE   Angiotensin-converting enzyme  
ACEi   Angiotensin-converting enzyme inhibitor 
AGE   Advanced glycation end product 
AGTR1a  Angiotensin II receptor type 1a  
BB-DP  BioBreeding-diabetes prone  
BB-DR  BioBreeding-diabetes resistant 
C/EBP-α  CCAAT/enhancer binding protein-α 
cAMP   Cyclin adenosine monophosphate 
CKD   Chronic kidney disease 
CYP27A1   Cytochrome p450, family 24, subfamily A, polypeptide 1 
CYP27B1  Cytochrome p450, family 24, subfamily B, polypeptide 1 
DAB2   Disabled-2 
DBP   Vitamin D binding protein  
DRI   Dietary reference intake  
ER   Endoplasmic reticulum 
FFAR   Free fatty acid receptor  
FGF23   Fibroblast growth factor 23 
GLP-1   Glucagon-like peptide 1 
GLUT2  Glucose transporter 2 
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GLUT4  Glucose transporter 4 
HAM   High-amylose maize 
HbA1c   Hemoglobin A1c or glycated hemoglobin 
HFD   High-fat diet  
HLA   Human leukocyte antigen  
IL-1   Interleukin-1 
IL-6   Interleukin-6 
KO   Knockout 
IOM   Institute of Medicine 
LDL   Low-density lipoprotein  
LPS   Lipopolysaccharides  
MAPK   Mitogen-activated protein kinases 
NEFA   Non-esterified fatty acid  
NF-kB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NOD   Non-obese diabetic 
NSP   Non-starch polysaccharide 
OP   Obese prone  
OR   Obese resistant   
PPAR-γ  Peroxisome proliferator-activated receptor-γ 
PTH   Parathyroid hormone 
PYY   Peptide YY 
RAGE   Receptor for advanced glycation end product 
RAS   Renin-angiotensin system  
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ROS   Reactive oxygen species 
RS   Resistant starch 
RXR   retinoid X receptor  
SREBP-1  Sterol regulatory element-binding transcription factor 1  
STZ   Streptozotocin 
T1D   Type 1 diabetes 
T2D   Type 2 diabetes 
TLR   Toll-like receptor  
TNF-α   Tumor necrosis factor-α 
TRPV6  Transient receptor potential cation channel, subfamily V, member 6 
VDR   Vitamin D receptor  
VDRE   Vitamin D response element  
VEGF   Vascular endothelial growth factor  
ZDF   Zucker diabetic fatty  
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APPENDIX B: CHAPTER 3 SUPPLEMENTAL DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Ingredient C RS 
g/kg g/kg 
Casein  200 200 
Corn Starch  550 0 
High-amylose maize 0 550 
Glucose  150 150 
Mineral mix (AIN-93G) 35 35 
Vitamin mix (AIN-93G) 10 10 
Corn Oil  50 50 
Choline bitartrate 2 2 
L-methionine  3 3 
Supplemental Table 1. Composition of the control (C) and 
resistant starch (RS) diets. 
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Supplemental Figure 1.  Renal megalin and Dab2 mRNA expression was not affected by 
diabetes or dietary resistant starch (RS) in ZDF. Quantitative real-time PCR analysis from 
the same rats as described in Figure 1 was conducted as described in Materials and Methods. 
A) Renal megalin expression in LCs, DCs, and DRSs. B) Renal Dab2 in LCs, DCs, and 
DRSs. Mean values for the 3 treatment groups were subjected to a one-way ANOVA. Data 
are expressed as means ± SEM (n = 7-8). Dab2, disabled-2; DC, Zucker diabetic fatty rat fed 
a standard semi-purified AIN-93G control diet containing 55% cornstarch; DRS: Zucker 
diabetic fatty rat fed a resistant starch diet in which the cornstarch was replaced with an 
equivalent amount of high-amylose maize; LC, Zucker diabetic fatty rat fed a standard semi-
purified AIN-93G control diet; ZDF, Zucker diabetic fatty. 
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Supplemental Figure 2. Renal CYP27B1 and CYP24A1 expression was not affected by 
diabetes or dietary resistant starch (RS) in Zucker diabetic fatty rats (ZDF). A) Renal 
CYP27B1 expression in LCs, DCs, and DRSs. B) Renal CYP24A1 expression LCs, DCs, and 
DRSs. Mean values for the 3 treatment groups were subjected to a one-way ANOVA. Data 
are expressed as means ± SEM (n = 7-8). DC, Zucker diabetic fatty rat fed a standard semi-
purified AIN-93G control diet containing 55% cornstarch; DRS: Zucker diabetic fatty rat fed 
a resistant starch diet in which the cornstarch was replaced with an equivalent amount of 
high-amylose maize; LC, Zucker diabetic fatty rat fed a standard semi-purified AIN-93G 
control diet; ZDF, Zucker diabetic fatty. 
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APPENDIX C: CHAPTER 4 SUPPLEMENTAL DATA 
 
 
 
 
 
 
Supplemental Fig. 1. Urinary creatinine in T1D rats was not affected by RS. All rats 
were fed experimental diets for 4 weeks as indicated in Materials and Methods. NDC, non-
diabetic rats fed AIN-93G diet; CS, T1D rats fed AIN-93G diet; LRS, T1D rats fed AIN-93G 
diet containing 5% RS; MRS, T1D rats fed AIN-93G diet containing 10% RS; HRS, T1D 
rats fed AIN-93G diet containing 20% RS. Data are means ± SEM (n = 6/group). Groups 
with different letters differ (P < 0.05).  
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Supplemental Fig. 2. Urinary albumin in T1D rats was not affected by RS. All rats were 
fed experimental diets for 4 weeks as indicated in Materials and Methods. NDC, non-diabetic 
rats fed AIN-93G diet; CS, T1D rats fed AIN-93G diet; LRS, T1D rats fed AIN-93G diet 
containing 5% RS; MRS, T1D rats fed AIN-93G diet containing 10% RS; HRS, T1D rats fed 
AIN-93G diet containing 20% RS. Data are means ± SEM (n = 4 – 6/group). Groups with 
different letters differ (P < 0.05).  
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APPENDIX D. Chapter 5 Supplemental Data 
 
 
Supplemental Table 1. Primer sequences used in real time-PCR assays. 
 
Gene Sequence (5’ to 3’) 
Angiotensin-converting enzyme 
 (ACE) 
Forward: CTTGACCCTGGATTGCAGCC 
Reverse: GTTTCGTGAGGAAGCCAGGA 
 
Angiotensin-converting enzyme 2 
(ACE2) 
Forward: GAATGCGACCATCAAGCGTC 
Reverse: GGCTCAGTCAGCATGGAGTT 
  
Angiotensin II receptor Type 1a 
(AGTR1a) 
Forward: AGTCCTGTTCCACCCGATCA 
Reverse: TCCAGACAAAATGCCAGCCA 
 
Angiotensin II receptor Type 2  
(AGTR2) 
Forward: GTAGGTTGAAGGCTCCCCAG 
Reverse: ATTCTGTGCTCGCTCCATCC 
 
Nephrin Forward: GATGAAGTGGAGAGAGCCTATG 
Reverse: GTGTGTGTGTGTGTGTGTATTG 
 
 
18s Forward: ACATCCAAGGAAGGCAGCAG 
Reverse: TTCGTCACTACCTCCCCGG 
 
 
GAPDH Forward: CTCTCTGCTCCTCCCTGTTCTA 
Reverse: GGTAACCAGGCGTCCGATAC  
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Supplemental Figure 1. RS did not improve renal histopathological scoring in ZDF rats. 
Data are expressed as mean ± SEM (n = 5). LC, lean Zucker rats fed the control diet; DC, 
ZDF rats fed control diet; MRS, ZDF rats fed diet containing 10% resistant starch; HRS, 
ZDF rats fed diet containing 20% resistant starch; ZDF, Zucker diabetic fatty.  
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